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INTRODUCTION 
Attention deficit hyperactivity disorder (ADHD) is the most common 
neurobehavioral disorder among children. It is the most common chronic 
disease condition among school children too. ADHD has been recognized from 
all the countries and from all the cultures. DSM V clearly defines the 
diagnostic criteria (WHO DSM5, 2016)1 and identifies three subtypes namely 
hyperactive-impulsive, inattentive and combined types. Despite the difference 
in terminology between ICD 10 and DSM5, the two systems agree on three 
core features namely over activity impulsiveness and inattentiveness. Majority 
of children with ADHD are brought to medical attention for academic 
difficulties. Despite having a good intelligence, these children fail to perform 
up to the mark in school. This further affects their future academic goals and 
careers. The academic difficulties can be explained solely by a wide range of 
subtle deficits these children possess, i.e. in the executive functions mediated 
by their prefrontal cortices.  
The problems due to ADHD are multiple. Apart from academic 
underachievement, affected persons also have problematic social and 
interpersonal relationship especially with family members as well as the peers 
leading to low self-esteem and worry. Approximately 40% may go in to the 
condition in adulthood (Mannuzza, Klein, Bessler, Malloy, & LaPadula, 1993; 
Weiss & Hechtman, 1979)2,3 with significant underemployment and increased 
risk of antisocial behavior. A 10 year follow up study done by Biederman and 
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Petty showed persistence of symptoms and functional impairments into 
adulthood. (Biederman, J., Petty, C. R. etal) 4 Compared to several other 
neurodevelopmental  disorders, ADHD possess a great advantage of response 
to treatment. Modern medicine has shown a great development in the 
management of these children from just seclusion and dismissal alone to 
amelioration of symptoms with the help of drugs. Administration of drugs, to a 
great extend allow the individuals to attain their full potential in all areas of 
life. 
Rationale for this study 
In a child suffering from Attention Deficit Hyperactivity Disorder, the 
impairments in executive functions were the major determinants of their 
occupational functioning and day to day performances. (Barkley and Fischer 
2011) 5. The aim of a physician treating a child with ADHD is to offer them the 
best modality of treatment that can improve the deficits and in turn raise their 
academic social and day to day life performances. Though there are multiple 
pharmacological options available it is difficult to predict who will respond 
optimally to which drug (Tasman p 761) 6. This uncertainty is captured by us in 
the form of a research question and since we felt cognitive performance as the 
most important domain as a therapeutic goal we have framed our question 
comparing the cognitive performance as the outcome using two important 
choice of interventions in management of ADHD namely Atomoxetine and 
Methylphenidate. 
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REVIEW OF LITERATURE 
HISTORY 
Sir Alexander Crichton was the first one to publish an article on children 
with deficits in attention, in 1798 titled “An enquiry into the nature and origin 
of mental derangements on attention and its diseases”. He described the 
constitutional deficit of attention as “incapacity of attending with a necessary 
degree of constancy to any one object, arising from unnatural or morbid 
sensibility of the nerves7. Later in 1902 George Still described children who 
were restless, impulsive, and inattentive with intense affective responses and 
conduct problems8. Still had associated it to brain damage and the popular 
belief persisted when after world war I, there happened an outbreak of 
encephalitis affecting20 million people and left with severe neurological 
sequel. Children who suffered from encephalitis exhibited hyperactivity 
restlessness inattention and impulsivity. Thus the condition received a new title 
of post encephalitic syndrome or post encephalitic behavior disorder.9 The 
similar pattern of symptoms was later named Minimal brain damage syndrome 
as it was believed to have occurred after the pandemic of influenza.10 As brain 
damage or dysfunction could not be documented in all such children the terms 
hyperkinetic and inattentive child was introduced11. Minimal brain dysfunction 
as described by Paul Sender included dysfunctions in the following parameters: 
attentions perception, cognition, learning, motor function, impulse control,  
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emotional regulation and interpersonal relations (Wood et all.,1976)12. In 1970, 
Sykes et al established the hallmark of the syndrome to be inattention, by 
means of Nero psychological testing (Sykes et al., 1973)13It was described first 
as a diagnostic entity in the International classification of disease and health 
problems ICD 9 and Diagnostic Statistic Manual (DSM II) in the name of 
hyperkinetic syndrome of childhood. In the former, ADHD was depicted as 
two separate conditions namely Minimal brain damage and hyperkinetic 
reaction of childhood10,11,14. In 1980s research showed that difficulty to sustain 
attention was the core feature of this condition and DSM III renamed the 
condition as Attention Deficit Disorder (ADD). The term hyper kinetic disorder 
in DSM II was replaced by Attention Deficit Disorder (ADD) in DSM III, 
which was finally replaced by the current term Attention Deficit Hyperactivity 
Disorder in DSM IV.  
Importance of the problem of ADHD: 
Magnitude of burden or prevalence of ADHD is an important chronic 
health problem considered as a diagnostic entity causing phenomenal distress 
to the affected child’s family. The economic loss to the society is considerable 
due to both direct cost of responding to the illness as well as the indirect cost 
due to loss of work days of parents and cost incurred due to the abnormal 
behavior of the affected ones, which can continue to the adulthood. The 
prevalence of ADHD differs across different settings and the rural urban 
difference is most significantly noted.  
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Attention Deficit hyperactivity disorder is one of the commonest 
neurodevelopmental disorder affecting children and adolescents. It is also one 
of the most researched medical disorders in children15.  
The deficits in ADHD and the subsequent adverse outcomes16 pose a 
significant financial burden to the child s family. 16 Thus the disease condition 
is per se regarded as a significant public health issue. 17  
Meta-analysis in 2007 shows a pooled prevalence of 5.29%17. Meta 
Regression analysis have shown the prevalence of ADHD worldwide to be in 
the range if 5.29%16 to 7.1%18 in children and adolescents and 3.4% in adults18. 
Rates of prevalence in extremes of age have not been much studied. Prevalence 
studies conducted in several countries show high variations: from a very low 
prevalence of 0.9% in Brazil19 to nearly 20% in Columbia20 
 The reasons for variations in prevalence across various regions may be 
due to the variability in definitions used by experts in these regions.21,22  
(Bird HR, Rohde LA)Academy of Child and Adolescent Psychiatry suggested 
the reason to be differences in methodology used by researchers in these 
areas.23 (Dulcan M)  
Magnitude of the problem: In America a pooled prevalence of 7.2% 
has been reported from a meta-analysis at national level24. From 
epidemiological studies it is shown that the prevalence in UK were 30.5, 88.9 
(192%) and 81.5 (167%) per 100,000; all figures being higher in males than 
females25. In India various community level studies show that the prevalence 
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varies from 2-3% in urban areas among school children (Rajeshwari Mannapur 
et al,2016) and 3.6% in the rural areas26 (13)  
Developmental impact of ADHD 
The developmental impact of ADHD has been a focus of study and its 
impact on cognitive competence especially in academic performance, social 
competence and occupational ability has been well described. The following 
picture illustrates the problems associated with ADHD and continuation in to 
the life span also. This implies the importance of life early inception of 
treatment in ADHD.  
A summary of problems associated with ADHD as a disorder across a 
person’s lifespan.  
 
 
 
 
Venkat Bhat , Lily Hechtman (2016) 27 
This concept of ADHD as a chronic disease and persistence in to 
adulthood has been described by other researchers also. Atilla Turgay et al  
(Jl of clinical psychiatry 2010)28 (15) described the lifespan persistence of 
ADHD and transition model to explain the neurobiology of the disorder. 
Gender differences in ADHD show that males are affected 2-3 times than 
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females and the inattentive subtype predominates in females whereas the 
hyperactive impulsive type in affected male children (Gaub & Carlson, 1997; 
Wolraich et al., 1996)29, 30 
DIAGNOSIS AND CLINICAL FEATURES 
The diagnosis of ADHD is essentially clinical and criteria based. There 
is no laboratory method for confirmation (Rudolf 11) The UK and US uses the 
different classification systems as ICD10 and DSM 5. 
DSM V diagnostic criteria for ADHD defines three types of 
presentations based on two criteria lists of nine symptoms of inattention and 
nine symptoms of hyperactivity. Children with six or more symptoms of either 
or both are diagnosed as ADHD and further subclassified as combined / 
predominantly inattentive /predominantly hyperactive impulsive subtype. In 
order to make a formal diagnosis symptoms must be present prior to age of  
12 and persist for more than 6 months and have an adverse impact on social 
academic or occupational activities in two or more settings. 
The diagnosis is not appropriate if the symptoms occur exclusively 
during the course of another primary psychotic mood anxiety substance or 
personality disorder but ADHD may coexist with pervasive development 
disorder. The core symptoms of the disorder being hyperactivity impulsivity 
and inattention. Hyperactivity refers to the excessive energy or activity with is 
inappropriate to the age and usually described as being driven by a motor. The 
excessive motor activity will be obvious in various settings like school home 
and playground and even during sleep and maybe reduced in novel situations or 
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while engaged in video games. As age advances the level of activity comes 
down, but the inner restlessness would persist. Previous diagnostic systems 
advocated the onset of symptoms to be present before the age of 7 to be 
diagnosed as ADHD. 
ETIOLOGY OF ADHD:  
Both genetic and environmental factors have been implicated in the 
causation of ADHD. A review of 20 twin studies estimated the mean 
heritability to be 0.76 which is comparable to bipolar disorder and 
schizophrenia (Faraone et al., 200531; Levy et al., 199732; Thapar et al., 199533). 
Family studies conducted by Beidermann et al and Faraone et al) 34also 
supported a genetic basis for the same. The genes widely implicated in ADHD 
are the Dopamine Transporter gene (DAT1 ) and the Dopamine D4 receptor 
gene (Swanson et al 2000 Gill et al 1997) .35, 36 The association of DAT1 gene 
have been replicated by various studies and its 10 repeat allele was found to be 
involved in transmission of ADHD from parents to their affected 
offspring36,37,38,39,40.Walmann et al demonstrated a combined subtype specific 
transmission of this particular allele in 1998 but such subtype variations could 
not be reproduced by subsequent studies41.. Within the DRD4 gene a 7 repeat 
allele polymorphism has been specifically associated.42-44 The above 
polymorphism is proposed to underlie the impaired postsynaptic and 
intracellular responsiveness to Dopamine. .Few other genes have been found to 
be associated with ADHD namely D4 D5 receptor gene, Dopamine and 
Serotonin transporter gene, DBH,SNAP 25 and HPR1B genes. 45-47 
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         Though a substantial portion of etiology is explained by genetic 
factors, evidence from studies had done by few authors like Banerjee et al 2007 
supports the possibility of involvement of environmental factors like lead 
exposure, maternal cigarette and alcohol exposure in utero, premature or low 
birth weight48. In 2002, Max et al suggested the possibility of traumatic brain 
injury to be a possible risk factor for ADHD49. Caspi and Moffitt in 2006 
suggested the possibility of gene - environment interaction50. Recent studies 
have suggested that ADHD might be the result of the interaction between 
genetic vulnerability and early life events, the latter accounting for a significant 
part of the variance in ADHD (Philipsen et al.,200851;Rucklidge et al.,200652; 
Spencer,200253) 
PATHOPHYSIOLOGY OF ADHD: 
Wender in 197454, proposed the catecholamine theory of Minimal brain 
dysfunction, followed on the same line by Levy who launched the dopamine 
theory of ADHD in 1991. Several lines of evidence support this hypothesis. 
First, the efficacy of stimulant drugs like amphetamine, methylphenidate in 
treatment of ADHD whose mechanism of action is facilitation of 
catecholamine transmission (Arnstein& Li.,200555 Shaywitz et al.,200156; 
Wender et al., 200157; Volkow et al.,200558). Secondly, in a PET study done by 
Volkow et al in 200959, symptoms of inattention was found to be associated 
with a reduction in dopamine synaptic markers- a strong evidence in favor of 
dopamine hypothesis of ADHD is that dopamine receptor coding genes have 
been proposed to be the candidate genes in ADHD (DR4,DR5,DAT1,DBH). 
The most investigated candidate genes have been DAT1, DR4, DR5 and DBH, 
 10 
and inconsistent results have been obtained from COMT, MAOA and DBH 
analysis. MRI studies of ADHD subjects demonstrated a smaller brain regions 
of dopamine receptors dense brain regions compared to healthy controls 
(Swanson et al.,2007)60. Furthermore, few studies have shown correlation of 
symptoms severity and measures of homovanillic acid (dopamine metabolite) 
in CSF of ADHD patients. 
Similarly, serotonin has been the other neurotransmitter implicated in 
ADHD, though evidence supporting it is few compared to dopamine. Molly 
Nikolas et al. note that the emotional dysregulation seen in ADHD is not 
mediated by dopamine or nor epinephrine. Serotonin is found to be related to 
impulse control and aggression. It was found that two variants of the serotonin 
transporter gene - 5HTTLPR, the “short” allelic variant and the “long” allelic 
variant, have been linked to ADHD and to the other disorders co morbid with 
attention deficit disorder, like mood disorder and conduct disorder. These 
5HTTLPR alleles result in either low or high serotonin transporter activity. 
Furthermore, a correlation between the 5HTTLPR and self-blame was found by 
Nikolas et al61. The combination of the genetic predisposition and self-blame 
were postulated to result in hyperactivity and impulsiveness symptoms. 
However, the serotonin neurotransmission was not found to have any relation 
with cognitive or inattentive component of ADHD.  
COURSE OF ADHD 
Regarding the long term course of ADHD many studies have shown that 
the symptoms continue even when they reach adulthood. Clinical features tend 
to reduce by 50% every 5 years during the period of 10-25 years.  
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Hyperactivity being the first symptom to recover as child grows up62,63. 
Initially regarded as a disorder of childhood, ADHD has been shown to persist 
in adulthood in 10 to 60%of cases (Zametkin, 1995)64. The rate of ADHD 
symptoms progressing to adulthood varies. While some authors report a rate of 
60% (Wood et al. 197665; Kessler et al. 200666, others report a rate as low as 
10%. In 2008, Young and Gudjonsson suggested that ADHD cases that persist 
into adulthood have generally more severe symptoms.67 Conversely, in 2009 
Karam et al proposed that compared to children with ADHD, adults with 30 
ADHD present with less externalizing symptoms but with a higher rate of other 
psychiatric co morbidities like substance abuse, major depressive disorder and 
anxiety disorder, which in turn might mask the impulsive, hyperactive 
symptoms and determine the prognosis of ADHD symptoms per se difficult.68 
The mystery remains to be unfolded whether the age-dependent symptom 
decline constitutes real remission or a methodological artifact &amp; our 
inability to study the masked symptoms of ADHD. 
COMORBIDITY IN ADHD: 
Gilberg et al reported from their study finding that ADHD presents with 
co morbidity in 60-100% of cases69. Among children, the most frequent co 
morbid condition being oppositional defiant disorder and conduct disorder, 
followed by autistic traits, motor in coordination problems, anxiety and specific 
learning disability.70 Among adults, ADHD is found to be highly co morbid 
with mood disorders (40%), including 20% bipolar disorder, anxiety disorders 
(50%) and substance use disorders (15%) (Kessler et al, 2006) (20). There is a 
significant risk of the use of substance of abuse in ADHD children when they 
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grow up into adolescence and adulthood. The risk factors for the same are 
family history of ADHD and substance use disorder or the presence of co 
morbid bipolar disorders. The debate on the role of continuous treatment in 
ADHD lowers the risk of substance use is ongoing.72 A prospective study 
comparing ADHD and controls showed a 18% risk of antisocial personality 
disorder and 16% risk of substance use disorder73 Co morbidities and a positive 
family history was found to be the highest predictors of psychopathology.74 
ADHD AND ACADEMIC FUNCTIONS 
Indian study conducted in Goa showed that most of the children with 
ADHD were brought with the complaints of poor scholastic performance and 
the parents showed great reluctance in accepting the illness model.75 A 
prospective 4 years follow up study of ADHD children showed that these 
children have significant deficits in cognition that adversely affects their school 
performance76. Studies show that the subtypes of ADHD differ in their clinical 
presentations and academic difficulties are more pronounced in the inattentive 
subtype secondary to impairments in attention77. A prospective study on 
ADHD males conducted by Mannuzza etal showed that ADHD subjects had 
high degrees of high school dropouts secondarily to an aversion to schooling 
and studies. Though employed, they were found to be far below to their normal 
counter parts in attaining top ranks in profession.78 
  Beidermann and Petty et al pointed out that sufferers from ADHD would 
tend to choose jobs demanding a lower levels of attention so as to masks their 
deficits.79Academic outcomes of such children and adolescents have been 
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widely studied and it shows higher suspension and detention rates and lower 
rates of academic achievements throughout school and college level.80-85 
Also, university students with ADHD encounter problems with tasks 
and processes that are synonymous with the requirements of higher education, 
such as study strategies, note taking, summarizing and outlining, test taking, 
test strategies, time management, concentration, motivation, information. The 
daily performance of these students on classroom tasks and homework is 
typically inconsistent and below that of their peers; up to 80% of students with 
ADHD have been found to exhibit academic performance problems (DuPaul & 
Stoner, 2002, 2003)86. In a longitudinal study, McGee and colleagues (1991)87 
followed pre-schoolers who were rated as hyperactive (a key symptom of 
ADHD) through to adolescence, and found that they had poorer reading ability 
than controls at ages 7 and 9. Rabiner and colleagues (2000)89 studied ADHD 
symptoms and reading achievement in 387 pre-school children. They found 
that inattention and hyperactivity was negatively associated with reading 
achievement, with the strongest correlations appearing with inattention. It 
seems that once at school, children with ADHD will struggle with academic 
work (McGee et al. 1991; Biederman et al. 1996; Rabiner et al. 2000).87,89,90  
The literature shows that school-aged children with ADHD experience 
an abundance of academic and educational problems (Biederman et al. 1996; 
Barry et al. 2002; Loe & Feldman 2007)90,91,92. Compared with controls, 
ADHD children are more likely to use remedial academic services and be 
placed in special education classes (Biederman et al. 1996) 90, and experience 
behavioural problems that lead to suspension or expulsion (LeFever et al. 2002) 
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93 Apart from academic difficulties, children with ADHD are at high risk of 
developing a wide range of impairments affecting multiple domains of 
psychopathology such as cognition, interpersonal, school, and family 
functioning. 
Neuro-imaging studies of children with ADHD have shown a decreased 
size of the prefrontal cortex (Hill et al. 2002; Mostofsky et al. 2002 94,95.As 
Prefrontal cortex is believed to be the storehouse of executive functions, there 
are expected deficits in certain prefrontal executive functions, such as response 
inhibition (Barkley 1997) 96 and working memory (Tannock 1998 28) 97 ADHD 
adults showed reduced activation in the left cerebellum and a trend for reduced 
activation in the contra lateral right prefrontal region during performance on a 
verbal working memory task (Valera et al 2005) 98. Kaufmann and Nuerk 
(2008) investigated specific aspects of academic difficulties experienced by 
ADHD individuals by looking at various components of mathematical 
processing99 There were no differences between the ADHD-diagnosed and 
control groups on explicitly trained simple and complex calculation skills, but 
the ADHD group did perform significantly worse on basic number processing 
abilities such as comparing the magnitude of single digit numbers. Merrell and 
Tymms (2001)100 found that children who exhibited symptoms of ADHD 
performed significantly worse than those who did not on Key Stage 1 tests of 
reading and mathematics. Similarly, Diamantopoulos and colleagues (2007) 
101found that, in a community sample, children’s ADHD symptoms were 
correlated with poor school performance. In a meta-analysis, Frazier and 
colleagues (2007)102 found that adolescents with ADHD displayed significantly 
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lower levels of academic achievement compared with controls. s. Mannuzza 
and colleagues (1993) found that at adult follow-up, men who were diagnosed 
with ADHD as children had completed on average 2.5 years less schooling 
than controls, and nearly one quarter of the ADHD group did not complete high 
school, compared with 2% of controls. Research shows that ADHD symptoms 
persist into adulthood, with between 11 and 40% of childhood cases continuing 
to meet criteria for the disorder in adulthood (Mannuzza et al. 1993)103. 
Systematic reviews conducted to anise the long term outcomes of children with 
ADHD found out a negative impact of symptom profile on various other 
domains like social functioning addiction self-esteem obesity and driving. 104 
NEUROIMAGING 
In the earlier stages imaging studies of ADHD utilized computerized 
tomography techniques which did not yield much significant differences from 
the normal other than frontal symmetry which was found to be characteristic of 
ADHD.(Nasrallah et al 1986) 105.  
Later imaging studies like MRI started to detect the subtle anatomical 
differences. Various brain areas particularly the right hemisphere were found to 
be reduced in size in ADHD children when compared to normal subjects  
(Castenallos etal 1996 a Filipeketal 1997b Hind 1990).106,107,108 A right > left 
fronto cortical asymmetry found in normal brains were not seen in ADHD 
subjects. (Castenallos 1996, Hynd 1990). 106,107 There has been corpus callosal 
volume differences notes in various studies. Both anterior109 and posterior 
regions of corpus callosum were found to be reduced in size 110 whereas later 
studies could not replicate the same.111Basal ganglia volumes also suffered 
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reductions. Castenallos and colleagues demonstrated that the absence of right< 
left caudate asymmetry in ADHD along with Lack of age related maturation if 
caudate n nucleus led to reduction of volumes. (Castenallos 1994 1996 a 
Mataro 1997) 112,113,114Other brain areas that suffered volume reductions are the 
Globus Pallidus (Singer et al1993)115 cerebellum116 and fronto parieto occipital 
white matter. Swanson et al was able to demonstrate a 10% reduction in frontal 
and basal ganglia structures as compared to normal subjects.(Swanson 
1998a)116All the structural imaging findings focused on to the frontal lobe in 
turn supports the neurochemical deficits located on the prefrontal cortices if 
these subjects117 
Electrophysiological research studies also demonstrated significant 
changes with respect to controls. An increase in slow wave activity and a 
reduction in fast wave activity was seen in ADHD cases and served to prove a 
generalized EEG slowing in ADHD children. This in turn depicts the 
underlying information processing deficits and poor cortical arousal 
mechanisms118. The specificity of EEG slowing in ADHD is questionable as it 
has also been demonstrated in children suffering from learning disabilities119. 
NEUROTRANSMISSION IN ADHD 
  Dopamine, one of the catecholamine hormone important in 
neurotransmission is proposed to be the major chemical substrate underlying 
symptoms of ADHD. There are various a pathway in the brain through which 
dopamine mediates neurotransmission. Cell bodies of dopaminergic neurons 
originate from the ventral tegmental area of midbrain and substantia nigra 
projecting into other areas as different pathways namely mesolimbic 
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tuberoinfundibular nigrostriatal and mesocortical These [pathways are 
important in regulating both emotions and other higher cognitive functions.  
The saliences of external stimuli are regulated by dopamine via these 
pathways. Similar to dopamine hypothesis of schizophrenia a dopamine theory 
of ADHD was also proposed by Wender in 1974 and later proven by Levi in 
1991.( J M Swanson et al 2007) 120 
Various evidences run in favor of this neurotransmitter being involved 
in ADHD including the various dopamine receptor coding genes being dis 
covered as the candidate genes in ADHD. (DR4, DR5, DAT1, DBH  etc) and 
the significant response to ADHD symptoms produced by stimulants that 
increases the synaptic dopamine concentration. Also imaging studies have 
shown volumetric reduction of brain areas rich in dopamine and dopamine 
synaptic markers in ADHD subjects. Finally, studies have shown correlation of 
symptoms severity and measures of homovanillic acid (dopamine metabolite) 
in CSF of ADHD patients (Castenallos et al) 121 
Serotonin is another hormone that plays a crucial role in regulating the 
release of dopamine in different pathways. Various serotonin transporter and 
receptor genes re found to be involved in genetic transmission if ADHD 
(Faroane et al 2005)122 Low levels of serotonin metabolites are seen in 
individuals with high levels if impulsivity and aggression which are important 
symptoms of ADHD. 
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 EXECUTIVE FUNCTIONS IN ADHD 
1. WORKING MEMORY 
Working memory (WM), as quoted by Goldman et al is the ability to 
keep information online during a short period of time (Bethesda et al).123 
Working memory is essential for retaining to a particular information by not 
getting distracted from external stimuli. Thus working memory deficits per se 
play a crucial role in easy distractibility seen in ADHD children (Barkley 
1997)124. Dopamine is one of the major neurochemical modulator of working 
memory, and stimulants that improve dopaminergic transmission helps in 
correction of these deficits to some extent. (Luciana M)125 The functional 
anatomy of working memory was studies using imaging studies by Schweitzer 
et al showed less specific activation of frontal areas in ADHD subjects when 
compared to controls. Also occipital region activation showed that there is a 
compensatory use of other brain areas to overcome the deficits (Julie B Switzer 
etal)126 Both phonological (verbal) and visuospatial working memory are 
significantly impaired in children with ADHD. (Mark D) 127 
2. RESPONSE INHIBITION 
It is considered as an individual s ability to voluntarily inhibit or 
suppress the dominant responses as and when required. Neurobiological 
correlation of this executive function parameter is evident in the right 
prefrontal cortical areas as supported by various functional neuroimaging 
studies. Right hemispheric prefrontal cortices inhibit the response whereas it is 
the function of basal ganglia to execute the responses. Patients with lesions of 
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right frontal lobe specifically inferior frontal gyrus pars triangularis part had 
shown slow performances in Stop Signal response tasks (Adam R et al) 128.The 
response inhibition scores in these signal tasks is inversely proportional to the 
intensity of damage to right IFC structures (Adam R Aron) 129There has been a 
proven finding that response inhibition is impaired In subjects with ADHD(Joel 
et al, Nigg et al,J Crossbie et al) 130.Meta analytic reviews done by Osterlaan 
etal supports the above finding. 130 Response inhibition deficits has been widely 
postulated as an endophenotype of ADHD. 131It has been proposed as the 
primary executive function deficit in ADHD due to the lower scores compared 
to selective attention. 
SUSTAINED ATTENTION 
It is the ability to sustain or maintain the attention span continuously for 
a particular period of time. The main neurobiological correlate of this executive 
function domain lies in the ventrolateral part of prefrontal cortex (Voisin J 
Lawrence et al).132 
A study to assess sustained attention in children with ADHD compared 
to controls using the continuous performance test showed that there was more 
number if errors, prolonged reaction time and comparatively more effort were 
allocated by ADHD children than controls. 133 fmri studies comparing children 
with ADHD and conduct disorder showed a dysregulation of ventrolateral 
frontocerebellar attention network in the former. Under activation of these 
areas were noted during tasks measuring sustained attention. Genetic 
correlation of sustained attention parameter was studied using the variants of 
Dopamine D4 receptor gene. Inheritance of the 7-repeat allele of the VNTR 
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was associated with a better performance scores in sustained attention tasks 
whereas Presence of the AA allele of -521 SNP indicated much lower scores. 
Research shows that sustained attention has a heritability component i.e. the 
ability to sustain one’s attention is partly inherited through genes. This also 
explains the deficits in sustained attention noted in diseases with genetic 
transmission including schizophrenia and ADHD.  
Twin studies have demonstrated the role of genetic component in 
mediating the former. 134 Executive function deficit manifest in various ways in 
an individual with ADHD,experiencing intense flaws in procrastination. They 
have a severe inertia of rest when a new task is to be started though it is very 
important to them.  
Keeping work off to the last minute is a common behavior observed in 
these individuals which is usually considered as a sign of laziness by others 
observing them. But the underlying cause for the behavior is defect in 
neurochemical regulation in ADHD. They tend to start off a work only when 
they find it truly appealing or frightening either out of passion or fear the brain 
supplies necessary neurotransmitters relevant for the task135,136 
Management of ADHD:  
BEHAVIORAL VS PHARMACOLOGICAL 
The treatment of ADHD should be multimodal and collaborative with 
the combined effort of teachers, parents and health professionals. (Irene 
M.Lowe etal).137 Psychopharmacological approach is one important strategy 
and is always combined with other lines of management like behavioral 
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therapy, psychotherapy. A comprehensive review of nonpharmacological 
interventions in the Indian setting was given in one of the recent review articles 
(Sujatha Satpathy et al 2016) 138. Extensive research has proven beyond doubt 
that medications control almost all symptoms of ADHD to some extend. (Lary 
S goldman et al) 139. Several studies have advocated the use of multimodal 
therapy for the long term treatment benefits of ADHD children, which 
combines pharmacotherapy with educational school based environmental and 
psychotherapeutic strategies. (RichtersJE, Statterfield etal).140 Behavior therapy 
alone has not provided much promising results when combined to 
pharmacotherapy or combination approaches. (Barkley et al) 141 
The treatment goals are primarily to address the core symptoms, and to 
address the cognitive psychological and social impairments so that the quality 
of life of the affected can be regained to fully functional status. The treatment 
depends on the age of the affected and coexisting mental health conditions. The 
history of Psychopharmacological treatment is traced to 1937 and over the last 
80 years much changes in treatment happened due to generation of research 
based evidence. Various RCTs, systematic reviews and metanalysis have 
resulted in well accepted professional guidelines. By all these guidelines 
psychostimulants constitute the mainstay in management of ADHD. The 
evidence base for stimulants is reasonably strong with mean effect size 0.8 to 
1(Allan Tasman page 760) 142 
GUIDELINES FOR MANAGEMENT OF ADHD 
The NICE Guidelines (UK), 2010 indicate that atomoxetine 
dexamphetamine and methylphenidate are all licensed and effective for 
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management of ADHD143.The Indian academy of Pediatrics guidelines (IAP 
2017) by consensus only prefer methylphenindate over atomoxetine as the 
initial preferred drug of choice144. The major limitation is that this is a 
consensus based and not evidence based. We can see that these guidelines 
differ in certain specific contexts and debates on diagnosis is also highlighted 
in some guidelines. 
AAP recommends FDA approved drugs for starting treatment145. The 
guidelines say that since the stimulants are extensively evaluated quantum of 
evidence is more while nonstimulant drugs though met the satisfaction criteria 
of FDA quantum of evidence is less. (Atomoxetine has an effect size of only 
0.7 while stimulants have effect size of 1) The adverse effects are also different 
for both group of drugs. The stimulant adverse effects are appetite loss, 
abdominal pain, headaches, sleep disturbance and sudden occurrence of cardiac 
death as a possibility especially among preschoolers. The MTA study also 
revealed concerns on impaired growth velocity. 
The adverse effects of atomoxetine include initial somnolence, GIT 
symptoms, increased suicidal thought and rarely hepatitis. Many studies 
involving Methylphenindate studied the effects among preschool children 
only146. So in order to understand the information on therapeutic benefit among 
older ones our study population was selected as children as well as adolescents. 
The NICE Guidelines (UK), 2010 indicate that atomoxetine dexamphetamine 
and methylphenidate are all licensed and effective for management of ADHD 
143The Indian academy of Pediatrics guidelines(IAP 2017) 144 by consensus 
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only prefer methylphenidate over atomoxetine as the initial preferred drug of 
choice. The major limitation is that this is a consensus based and not evidence 
based. We can see that these guidelines differ in certain specific contexts and 
debates on diagnosis is also highlighted in some guidelines. 
Drugs used for ADHD management  
The pharmacological management of ADHD include tricyclic 
antidepressants, (Imipiramine, desimipiramine, nortryptiline), noradrenaline 
uptake inhibitors (Atomoxetin), Aminoketone antidepressants like Bupropion 
and Alfa 2 agonists like clonidine and Guanfacine. The most widely prescribed 
drugs for ADHD treatment in children and adults are psychostimulants namely 
amphetamines and methyl phenindate 
Stimulants are the first line drugs for pharmacological management of 
ADHD non-stimulants are indicated when stimulants are not effective or there 
are adverse events to stimulants or when there is coexisting condition. 
(Rudolf)In UK the current management strategy is changing. They primarily 
used ICD classification indicating hyperkinetic disorder. Now most of the 
doctors in UK also change to DSMV and the emphasis is more on inattention 
than over activity. Hyperactivity was found to be improving with time but 
inattention persisted causing significant impairments in academic activities of 
these children. As a consequence of this the prescription for stimulant 
medications has increased significantly.  
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Stimulant drug: Methyl Phenindate 
The two group of stimulant drugs approved by US FDA for the 
treatment of ADHD are Amphetamines and Methylphenindate. They both act 
by increasing Dopamine and Norepinephrine in the synaptic cleft. 
Methylphenindate is a dopamine nor epinephrine reuptake inhibitor while 
amphetamine blocks the reuptake of both dopamine and norepinephrine as well 
as facilitates dopamine release through reverse transport.  
Methylphenindate is available as both Immediate and extended release 
forms as tablets, an hour of administration and peak levels are reached in 1-3 
hours and slowly disappears after 5 hours. OROS MPH is an osmotically 
release oral system that releases stimulant via an osmotic pump in an ascending 
dose curve over a 10-12 hour period MPH is metabolized the gut wall by 
plasma esterase and variations in the human CES 1 gene coding for 
hydrolyzing enzyme leads to inter individual variations in metabolism of the 
drug. Side effects which are commonly encountered include reduced appetite 
weight loss, delayed sleep, headache stomach ache increase in pulse rate and 
blood pressure.  
Infrequent side effects being motor tics, unmasking of Tourette’s 
syndrome and rebound of symptoms (which can be avoided by long acting 
preparations). A small scale study conducted by Johnston etal showed lack of 
significant rebound symptoms in children receiving Methylphenidate147. Rare 
side effects include visual and tactile hallucinations, priapism, choreiform 
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movements and other self-directed behaviors Cardiovascular side effects 
warrants an initial cardiac evaluation in children at risk of adverse cardiac 
events.  
Stimulants are considered as the first line management of symptoms of 
ADHD. Various clinical trials conducted have proven significant improvement 
in 65-75% of children with ADHD148Methylphenindate offers benefit in 
symptoms by raising extracellular dopamine levels in prefrontal cortex149 via 
blockade of Dopamine and Norepinephrine transport systems.150 151  
Thus lack of motivation mediated via dopaminergic neurons and poor 
attention via Norepinephrine neurons are being corrected through 
administration of a single drug. The drug is formulated and marketed in two 
racemic forms namely d-threo and l-threo forms.It exerts its major actions via 
binding of d –threo enantiomeric form into the DAT receptors. The former is 
concentrated more towards the basal ganglia whereas l-threo is found in all 
regions of the brain.152 
Stimulants have also shown to improve co morbid symptoms of anxiety, 
nail biting and irritability153Meta analytic reviews have shown that stimulants 
exert a much higher fold positive effect on cognition and behavior than on 
academic impairments154.Apart from ADHD, stimulants are widely used in 
several other conditions like narcolepsy, pain control155major depressive 
disorder156 and in Dementia for the treatment of apathy associated with 
it157.Other drugs like Tricyclic antidepressants, Bupropion and alpha blockers 
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are also found to be beneficial in ADHD 158-160. Lithium and neuroleptics also 
play a role in symptom reduction but are considered as second line due to the 
profound adverse effects. 161,162 
Nonstimulant drugs: ATOMOXETINE 
Over the last 50 years or more psychostimulant drugs were considered 
as the standard treatment of ADHD. In the year2002, first non-stimulant drug 
was launched with approval named Stattera (Atomoxetine). Since then 
Atomoxetine was widely prescribed for ADHD children. 
PHARMACOKINETICS 
The major metabolite of Atomoxetine was found to be named as4 
hydroxy atomoxetine, which is formed principally via metabolism through 
CYP2D6 enzymes and also through CYP1A,CYP2A6 CYP2B6 etc 163.An 
alternative minor metabolism product named N Desmethyl atomoxetine was 
also identified formed via CYP2C19 metabolism.164 When administered to 
normal subjects the clearance pattern of Atomoxetine showed a bimodal 
distribution165 
EFFICACY AND SIDE EFFECT PROFILE 
Efficacy trials of Atomoxetine were conducted which rated symptom 
improvement using Conners adult rating scale. All studies showed statistically 
significant superiority of Atomoxetine when compared to placebo. 166-172  
A systematic review done by Joshua etal found thatAtomoxetine has a lower 
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potential for abuse as it might not leadto dopaminergic surge in Nucleus 
Accumbens as done bystimulant medications 173 
METHYLPHENINDATE AND EXECUTIVE FUNCTIONS 
Animal studies in rats have demonstrated improvements in prefrontal 
cortex execute e functioning following administration of methylphenidate. 
Even in patients suffering from progressive neurological illness a 10 mg dose 
of methylphenidate was shown to have significantly improved scores of 
cognitive functioning.174 An optimal dose of 0.5 mg per kg of methylphenidate 
was found to be improving the deficits in self ordered spatial working memory 
task in a case of adult ADHD175. Studies in adult ADHD also showed 
significant improvements in response inhibition scores following 
methylphenidate administration176 During the late 1980s a major issue of 
concern was that whether stimulants like methylphenidate lead to impairment 
rather than improvements in cognitive flexibilities which is defined by the 
ability to shift suddenly from one concept to another as per situational needs; 
even hypothesis were formulated supporting the same177-179. Later a 
randomized double blind placebo control trial was conducted in 28 children 
with ADHD and finding of which disproved the above hypothesis. They also 
found a linear dose response model for motor activity but a central u shaped 
one for inhibitory control180 .Various executory function parameters like set 
shifting spatial working memory and response inhibition was found to be 
significantly improved after administration of Methylphenidate in normal 
adolescents181 and in children and adults with ADHD182.Even though domains 
like spatial working memory planning etc. was improved by methylphenidate 
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significantly attention and fluency domains suffered .there was good 
performance showed in novel tasks requiring spatial executive function 
whereas already established domains were affected adversely. This conflicting 
result were thought to be due to the duality in various arousal mechanism 183 
Studies done by Tannock etal proved that Methylphenidate 
administration lead to significant improvements in inhibition of inappropriate 
responses suggesting its role in the modulation of central inhibitory 
processes184A double blind placebo control trial of methylphenidate in 14 
ADHD children showed improvements in set shifting, spatial working memory 
and visual search tasks185In 2013 a meta analysis of nearly 60 studies on the 
role of methylphenidate in executive function showed that it was superior to 
placebo in improving Neuroimaging study was done to examine the changes in 
cerebral blood flow after administration of methylphenidate showed regional 
cerebral blood flow reductions in the dorsolateral prefrontal cortex and 
posterior parietal cortex with enhancement of working memory measures. 
Also, they found that the degree of enhancement was directly proportional to 
the baseline scores. 186  
Few studies have shown that executive function parameters like 
response inhibition187 planning, working memory and response inhibition were 
not improved by methylphenidate 188 
Contrary to predictions, acute MPH failed to improve performance on 
neuropsychological tasks with a prominent executive component. This absence 
of effect was observed on sensitive tests of inhibition, working memory, 
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strategy formation, planning, and attentional set-shifting. These findings are 
striking in that they contradict the existing literature. Specifically, the 
hypothesis that MPH selectively enhances performance on neuropsychological 
tasks with a prominent executive component was not supported. 
Contrary to predictions, acute MPH failed to improve performance on 
neuropsychological tasks with a prominent executive component. This absence 
of effect was observed on sensitive tests of inhibition, working memory, 
strategy formation, planning, and set-shifting. These findings are striking in 
that they contradict the existing literature. Specifically, the hypothesis that 
MPH selectively enhances performance on neuropsychological tasks with a 
prominent executive component was not supported. 
Contrary to predictions, acute MPH failed to improve performance on 
neuropsychological tasks with a prominent executive component. This absence 
of effect was observed on sensitive tests of inhibition, working memory, 
strategy formation, planning, and set-shifting. These findings are striking in 
that they contradict the existing literature. Specifically, the hypothesis that 
MPH selectively enhances performance on neuropsychological tasks with a 
prominent executive component was not supported. 
Randomized control trial of children with ADHD and reading disorder 
showed significant improvements in set shifting parameters after the 
administration of 0.3 to 0.4 mg per kg of methylphenidate189Another study 
comparing the effect of drug and physical exercise in 25 ADHD children 
found that there are not much improvements in domains of sustained attention 
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as measured by the continuous performance task, whereas vigilance and 
reaction time improved. 190 
ATOMOXETINE AND EXECUTIVE FUNCTIONS 
Atomoxetine was found to cause benefit for many children and 
adolescents with ADHD.A study on Atomoxetine s role in executive functions 
was conducted In National Taiwan University Hospital, with 30 patients and 
found that after 4 weeks of treatment there has been improvement in 
parameters like response inhibition ,sustained attention and set shifting. After 
12 weeks other parameters like working memory,problem solving spatial short 
term memory and planning showed significant improvements. 191.Another study 
by De Jong etal involving 20 ADHD +RD children of Netherlands compared 
Atomoxetine to placebo over a 4 weeks period. They found significant 
improvements in visuospatial working memory and minor improvemnts in 
response inhibition when compared to placebo.192 Chamberlein etal 
demonstrated improvements in inhibition and working memory in 22 adult 
ADHD cases.193 Thomas E Brown and colleagues in 2016 investigated the 
effects of Atomoxetine in adults after six months of therapy using a self report 
questionnaire. They found statistically significant improvements in five clusters 
of executive functions compared to placebo, namely utilizing working memory, 
Focusing for Tasks, Modulating Emotions, Organizing and Activating to Work, 
Regulating Alertness and Effort. They also suggested that the impact of 
administration if Atomoxetine to ADHD subjects was found positively 
correlated in various areas of life viz, drivng, education, social functions, 
employment and household routines.194 In 2012, a study conducted by 
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Wehmeier compared the efficacy of Atomoxetine over placebo by 
administering a continuous performance test which was computer based and 
coupled with a motion tracking device in 125 children of 6-12 years age group 
suffering from this condition. Therapy was initiated at the dose range if 0.5 mg 
per day slowly titrated to reach a maximum diose of 1.2 mg per day. After 
8weeks of therapy statistically significant improvements were shown in  
reaction time variation, commission error rates, mean RT etc. Also they 
assessed symptom improvement using ADHD rating scale and found 
significant improvements. Impression Severity in ADHD and Weekly Rating 
Oid Evening and Morning Behgaviour (WREMB) all of which showed 
improvement in symptom scores of hyperactivity and inattention195 
ATOMOXETINE AND MPH COMPARISON IN EXECUTIVE 
FUNCTIONS 
             Psychostimulant medications have been the first line of therapy for the 
last 60 years. An added benefit of increased effect on teacher rated symptom 
reduction was reported for methylphenidate. (Manfred Gerlach et al (2017) 196 
Recently Cochrane review doubted this added benefit and later this conclusion 
of refuting the benefit of methylphenidate was withdrawn by Cochrane group. 
Ole Jakob Storeb (2015) 197. The major criticisms for the review was laid down 
by The European Network of Hyperkinetic Disorders(EUNETHYDIS) 
regarding Cochrane review of ADHD children 198 to 204. There are many studies 
published in different settings on comparing methylphenidate and atomoxetine. 
Advantages and disadvantages of use also have been mentioned. Shaheen et 
al(2012) 205 after a detailed review mentions the increased chance of misuse of 
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methylphenidate by young adults. The comparative effectiveness has been 
investigated in trial setting specifically, atomoxetine and methylphenidate and 
the justifications for choice of therapy as first line drug, review of what is 
recommended in standard treatment guidelines, give recent studies available on 
this.  
An open label study was conducted by Yildiz etal in 2011 comparing 
both these drugs in terms of efficacy side effect profile tolerability and safety. 
Even though both the drug were found to be efficacious in improving 
symptoms, minor differences were noted in the individual tests. OROS MPH 
was found to be superior to Atomoxetine in terms of strop 5 corrections. Also, 
the teacher and clinician rating scales showed a higher improvement scores 
with Methylphenidate. Similar studies conducted by Kemner etal and Newcorn 
etal showed similar findings, with respect to higher efficacy profile f 
Methylphenidate.206,207 While comparing the side effect profile Yildiz etal 
noted many differences. Despite the broad side effect profile majority of the 
children continued medication without fail. GI side effects were mostly 
reported in children receiving Atomoxetine whereas insomnia was the 
significant side effect in Methylphenidate group208. 
Animal studies comparing these two drugs showed improvements in 
executive functioning with these two drugs in monkeys. It was postulated t be 
the result if activation of adrenoceptors and dopamine receptors situated in the 
prefrontal cortices of these animals209. A randomized control trial comparing 
stimulants non stimulants and SSRI using a single dose in adults in improving 
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response inhibition was carried out by Sanjay Nandam .they found a superior 
level of enhancement of response inhibition as evidenced by reduced stop 
signal reaction time and response time variability with Methylphenidate 
compared to other drugs210 Atomoxetine, being a selective presynaptic NE 
inhibitor do not cover a broad areas as Methylphenindate,the reason being the 
minimal striatal Norepinephric innervation211. Hsing Chang randomized adults 
receiving two drugs into equal groups and applied Cambridge 
neuropsychological battery for assessment. Both the groups showed similar 
improvements in executive functions except superiority of Atomoxetine in 
spatial planning212. A meta analysis conducted in 2011 pooling all the similar 
studies showed that when compared to efficacy and acceptability, both the 
drugs are almost equal.But OROS MPH has found to be having superior level 
of efficacy when compared to Atomoxetine and IR MPH. They have also 
advocated the use of Atomoxetine as a second line drug and at higher dosages 
for maximum results213. 
Newcorn etal in 2008214 conducted a comparative study to assess the 
variation in the symptom response between two drugs and found that 
Methylphenidate was superior to Atomoxetine in that regard. (56% vs 45%). A 
study in Taiwan compared the executive function improvements with both 
drugs and found both drugs improved the executive functions and helped return 
the working memory back to that of normal (Li Yang Etal).215  
The details about the similar study findings will be discussed in the 
discussion section. 
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RESEARCH QUESTION AND HYPOTHESIS 
        To evaluate the difference in cognitive performance produced by 
Methylphenidate and Atomoxetine in children with ADHD after four weeks of 
starting treatment (both in standard pharmacological doses and other baseline 
parameters being comparable). The null hypothesis is that Methylphenidate is 
not significantly different in terms of  increased working memory and 
executive functions after four weeks of starting treatment compared to 
Atomoxetine( in both standard pharmacological doses and other baseline 
parameters being comparable).  
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AIMS AND OBJECTIVES 
   AIM:  
 To assess the difference in cognitive performance of children with 
ADHD between Methylphenidate and Atomoxetine after a period of 4 weeks. 
OBJECTIVES 
1. To assess working memory and other executive functions in children  
with ADHD 
2. To reassess the above parameters after four weeks of initiation of 
pharmacological treatment. 
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STUDY CENTRE 
Institute of Child Health is a quaternary care Institute that caters to 
nearly three states of South India namely Tamil Nadu, Andhra, parts of Kerala 
and Karnataka. The Department of Child Psychiatry was established more than 
half a century ago in this Institute. It is and an academic institution where 
training is being given to postgraduates and other paramedical staff every year. 
The study was conducted at the Child Guidance Clinic of the Department of 
Child Psychiatry, Institute of Child Health and Hospital for Children, Madras 
Medical College, Chennai, Tamil Nadu, India. The institutional ethical 
committee had approved the study proposal on 7/2/2017. (for the Certificate of 
approval and details of informed consent forum refer Appendix 2). 
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METHODOLOGY 
A double blind prospective comparative interventional design was 
adopted and all the children attending the Child Guidance Clinic out patient 
department during the period of March –September was included in the study. 
Patients in the age group 7-12 years were eligible to participate if they were 
diagnosed as ADHD as per the DSM V criteria and parents were consenting to 
participate in the study and were excluded if they had Intellectual Quotient 
below 70, were suffering from chronic medical conditions or harbored any 
significant cranial pathology. Thus a total of 90 children were included in the 
study out of which 36 had dropped out from the study due to loss at follow up. 
Thus the ultimate sample size turned out to be 54 with 27 cases receiving 
Atomoxetine and 27 receiving Methylphenidate. The reasons of drop outs 
being hesitancy in continuing drugs, not responding to phone call, change of 
residence, difficulty to come for review due to distance and travel time etc. The 
study was carried out for a period of 6 months extending from March to 
September 2017 after obtaining institutional ethics committee approval 
          All the study participants who met the DSM V diagnostic criteria, 
inclusion criteria and filtered using the exclusion criteria were subjected to the 
fixed/standard neuropsychological battery of tests by the investigator. 
After completion of the tests, treatment was allocated to the study 
subjects using simple randomization method. Children were asked to pick a 
token from a box containing equal number of tokens named 1 and 2. Prior to 
the start of the study, both the drugs boxes were emptied and sealed separately 
into similar packets and was distributed to the subjects by a non-medical staff. 
Those who picked the lot number 1 would receive one drug and number  
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2 would receive the other dividing the drugs equally into two arms. Thus the 
investigator, co investigator and the patients were all blinded to the treatment 
they received. The parents were contacted over phone and ensured regular drug 
intake. They were followed up after two weeks for assessment of symptoms. 
After four weeks of treatment completion they were reevaluated using the same 
tests in the same order as applied before.  
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METHODS OF DATA COLLECTION AND DESCRIPTION OF TOOLS 
USED FOR COLLECTION 
All the children and adolescents of the age group 7-12 years presenting 
to the Child Guidance Clinic Outpatient clinic of Institute Of Child Health, 
Chennai during the period of March to September were evaluated in detail and 
administered parent and teacher Vanderbilt rating scale. Those children who 
met the sufficient score (6/9 hyperactivity or 6/9 inattention) in at least two 
different settings were diagnosed as ADHD and all those who met the above 
mentioned selection criteria was initially subjected to IQ assessment which was 
carried out by a clinical psychologist. After ruling out intellectual disability, a 
date for neuropsychological assessment was fixed within a week as per the 
patient s convenience. Investigator administered the test battery to every child 
before the start of treatment and recorded the test results and time taken for 
each test as pre drug values. The administration of tests were carried out in a 
spacious, well ventilated and aerated room after ensuring that child had his /her 
meal with the child and investigator alone in the room avoiding all other 
possible distracters. A friendly talk was initiated for few minutes to make the 
child relaxed and comfortable. All the tests were explained in detail in their 
mother tongue and demonstrated with examples before administration. For 
younger children and children of other states mother s help was sought for 
explaining the test procedures. All doubts were clarified simultaneously and 
maximum encouragement was given to perform up to their full potential. For 
children who were not able to sustain their attention for all the tests, sessions 
were broken up as per their convenience. 
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INTERVIEW PROCESS:  
The data collection was done by a clinical interview using a semi 
structured Interview Proforma (Appendix 1) During the interview it was further 
probed for ante/prenatal complications, any first degree relatives with ADHD 
or history of substance abuse among the family members. Temperamental traits 
were assessed in detail. Social and family history was collected from the 
verbatim reporting of the mother in the presence of one more family member. 
TOOLS USED FOR ASSESSMENT 
1. DSM V CRITERIA 
It is a used as a classification and diagnostic tool, the latest edition of it 
being updated by American Psychiatric Association in 2013 is being used to 
select the cases (Appendix 3) 
2. ASSESSMENT OF SEVERITY OF ILLNESS USING VANDERBILT 
ASSESSMENT SCALE (APPENDIX 4) 
This behavior assessment scale was selected because it is the most 
commonly used one and sufficiently validated for Indian population. Both the 
teacher version as well as for the parents were translated and back translated 
and used. 
3. INTELLIGENCE ASSESSMENT USING WECHSLER’S 
INTELLIGENCE SCALE FOR CHILDREN  
For IQ assessment, Weischlers Intelligence scale for children WISC 1V 
INDIA have been administered by a trained psychologist in our Institute. WISC 
IV INDIA is an Indian adaptation of the WISC 1V UK. It provides subtest and 
composite scores that represent inte4llectual functioning in specific cognitive 
domains as well as composite scores that represents general intellectual ability. 
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The average split half reliability coefficients ranged from 0.70 to 0.90 with 
most in the range of 0.81 to 0.90 therefore indicating good reliability(6). 
4. NEUROPSYCHOLOGICAL TEST BATTERY 
For the assessment of executive functions, standard or fixed battery 
known as NIMHANS Neuropsychological Battery for Children was used. All 
the tests used from the battery has high test retest reliability and validity. 
The individual tests are as follows- 
1. N BACK TASK (VISUAL) AND VISUOSPATIAL WORKING 
MEMORY SPAN TASK TO ASSESS VISUOSPATIAL WORKING 
MEMORY AND WORKING MEMORY SPAN  
(APPENDIX 5, 6)  
Working memory is a cognitive component with limited span of 
memory that is responsible for temporarily holding information. For assessing 
visuospatial working memory two tests have been used with N back task part 
one and two and Visuospatial working memory task which also measures 
working memory span and attention. 
2. N BACK VERBAL TASK TO ASSESS VERBAL WORKING 
MEMORY (APPENDIX 7) 
Verbal memory was tested using another two sets of N back tests where 
the child s ability to retain verbal information in working memory was 
assessed. 
3. STROOP TEST FOR ASSESSING RESPONSE INHIBITION 
(APPENDIX 8) 
Cognitive functioning in the form of Response inhibition or impulse 
control was assessed using Stroop test. It also measures selective attention, 
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cognitive flexibility and processing speed. For children with difficulty in 
reading words, Go No Go test was used (Appendix 11). 
4. COLOUR TRAIL TEST A AND B TO ASSESS SET SHIFTING AND 
FOCUSED ATTENTION (APPENDIX 9) 
       Two sets of Color Trail making tests were carried out wherein the child 
was expected to connect the numbers initially and then to connect by alternate 
colors from one to another. It measures set shifting and focused attention. Also, 
time taken for the test measures the processing speed. 
5. DIGIT VIGILANCE TEST TO MEASURE SUSTAINED ATTENTION 
(APPENDIX 10) 
        It is a test that measures the ability to sustain his /her attention for a 
prolonged period over a specific task. The child is instructed to select and 
cancel two particular numbers alone out of a big set of random numbers. The 
speed of processing the task is also compared. 
Handling nonresponse or dropouts  
Nonresponse is a challenging problem in management of any chronic 
disease and specially in monitoring the effect of interventions. Pitfall in 
monitoring the effect of treatment may be due to lack of communications and 
lack of understanding the disease and prevailing misconcepts due to inherent 
beliefs or prejudices already in occurrence in the community. This is especially 
relevant in the developing country setting. As immediate results are not explicit 
many may stop contact with health facility. This nonresponse rate in 
psychiatric research varies from 1-30% and in this study also a nonresponse 
rate of 20% were expected. The dropouts were specially followed up using 
repeated calls and home visits in selected cases. 
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STATISTICAL ANALYSIS 
The data was entered in Microsoft Excel spreadsheet (Appendix 12) and 
was analyzed using STATA 10 and Windows version. 16 The data was first 
cleaned and records with missed columns were omitted from analysis. The 
information collected was looked for missing values and incongruence in 
information collected. As there were considerable omissions for Stroop test and 
Go in Go these columns were deleted from records.  
Descriptive statistics was first attempted for means and proportions 
wherever indicated. Continuous variables like age, intelligence quotient was 
analyzed using means and standard deviation. Standard tests of significance 
like t test and ANOVA was used for normally distributed data and Wilcoxon 
rank test was used for non-normal or skewed data. Fischer’s exact test was used 
instead of chi-square test when the data was sparse in quantity.  
Conventional cutoff of 0.05 was taken for significance  
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RESULTS 
SOCIODEMOGRAPHIC CHARECTERISTICS 
AGE GROUP 
 
Sl No. Age Group Frequency Percent 
1 7,8 16 29.6 
2 9,10 15 27.8 
3 11,12 23 42.6 
 
 
 
In our study, we assessed children between the age group 7-12 years 
majority were in the age group of 11-12 years. (42.6%) 
 
 
 
 
 
 
29.6
27.8
42.6
AGE GROUP
1 2 3
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GENDER 
 
Sl No. Sex Frequency Percent 
1 Male 44 81.5 
2 Female 10 18.5 
 
 
 
Out of the total sample of 54 children, 81.5% were males and the rest 
were females. 
 
 
 
 
 
 
 
81.5
18.5
GENDER
1 2
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RELIGION GROUP 
 
Sl No. Religion Frequency Percent 
1 Hindu 46 85.2 
2 Christian 3 5.6 
3 Muslim 4 7.4 
4 Orphan 1 1.9 
 
 
 
The set consists of 85.2% of Hindus, 5.6% of Christians, 7.4% of 
Muslims and one orphan child. 
 
 
 
85.2
5.6
7.4
1.9
RELIGION GROUP
1 2 3 4
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Distribution of Sub Type ADHD 
Sl No. 
 
Type of 
ADHD 
 
Frequency Percent 
1 Inattention 12 22.2 
2 Hyperactive 5 9.3 
3 Combined 37 68.5 
 
 
 
When categorized into subtypes, most of our sample belonged to the 
combined subtype (68.5%), 22.2% inattentive and the rest minority as 
hyperactive subtypes. 
 
 
22.2
9.3
68.5
TYPE OF ADHD
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SIGNIFICANT RESULTS OF METHYLPHENINDATE -
IMPROVEMENT FROM BASELINE-SIGNIFICANT RESULTS 
 
 
 
 
  
1 2 3 4 5
PRE 49.66667 9.93354 51.61619 29.24798 70.08535
POST 25.48148 3.751304 19.49235 17.77057 33.1924
0
10
20
30
40
50
60
70
80
DIGIT VIGILANCE - ERROR
PRE POST
1 2 3 4 5
PRE 7.777778 0.2578308 1.339728 7.247799 8.307757
POST 8.296296 0.1672197 0.8688992 7.952571 8.640021
0
1
2
3
4
5
6
7
8
9
10
VERBAL N BACK1 - HIT
PRE POST
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1 2 3 4 5
PRE 1.222222 0.2578308 1.339728 0.6922434 1.752201
POST 0.6666667 0.1601282 0.8320503 0.3375185 0.9958148
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
VERBAL N BACK1 - OMISSION
PRE POST
1 2 3 4 5
PRE 5.185185 0.3501609 1.819489 4.465419 5.904951
POST 6.296296 0.281504 1.462738 5.717657 6.874936
0
1
2
3
4
5
6
7
8
VERBAL N BACK2 - HIT
PRE POST
 50 
 
 
 
 
 
 
1 2 3 4 5
PRE 3.851852 0.3608462 1.875012 3.110122 4.593582
POST 2.703704 0.281504 1.462738 2.125064 3.282343
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
VERBAL N BACK2 - OMISSION
PRE POST
1 2 3 4 5
PRE 2.851852 0.5815386 3.021763 1.656482 4.047222
POST 1.555556 0.3389835 1.76141 0.8587651 2.252346
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
VERBAL N BACK2 - COMMISSION
PRE POST
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1 2 3 4 5
PRE 2.703704 0.5058485 2.628466 1.663917 3.74349
POST 1.518519 0.3083379 1.602171 0.8847208 2.152316
0
0.5
1
1.5
2
2.5
3
3.5
4
VISUOSPATIAL N BACK TASK1  -
OMISSION
PRE POST
1 2 3 4 5
PRE 3.148148 0.59366 3.084748 1.927863 4.368434
POST 1.851852 0.3405363 1.769478 1.151869 2.551834
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
VISUOSPATIAL N BACK TASK1 -
COMMISSION
PRE POST
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1 2 3 4 5
PRE 4.518519 0.3262948 1.695477 3.84781 5.189227
POST 5.259259 0.3907499 2.030396 4.456061 6.062457
0
1
2
3
4
5
6
7
VISUOSPATIAL N BACK TASK2 - HIT
PRE POST
1 2 3
OBSERVED 4 15 8
SUM RANKS 59 283 36
EXPECTED 171 171 36
0
50
100
150
200
250
300
VISUOSPATIAL WORKING MEMORY SPAN2
OBSERVED SUM RANKS EXPECTED
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1 2 3 4 5
PRE 138.5556 19.76092 102.6807 97.93641 179.1747
POST 0.5555556 0.2285426 1.187542 0.0857795 1.025332
0
20
40
60
80
100
120
140
160
180
200
TRAIL A - TIME
PRE POST
1 2 3
OBSERVED 8 2 17
SUM RANKS 181.5 43.5 153
EXPECTED 112.5 112.5 153
0
20
40
60
80
100
120
140
160
180
200
TRAIL A - ERROR
OBSERVED SUM RANKS EXPECTED
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1 2 3 4 5
PRE 2.222222 0.5265956 2.736271 1.139789 3.304655
POST 0.7777778 0.2632978 1.368136 0.2365614 1.318994
0
0.5
1
1.5
2
2.5
3
3.5
TRAIL B - TIME
PRE POST
1 2 3
OBSERVED 16 4 7
SUM RANKS 302 48 28
EXPECTED 175 175 28
0
50
100
150
200
250
300
350
TRAIL B - ERROR
OBSERVED SUM RANKS EXPECTED
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ATOMOXETINE PRE -POST COMPARISON-
SIGNIFICANT RESULTS 
 
 
 
1 2 3 4 5
PRE 958.0741 58.09293 301.8597 838.6623 1077.486
POST 828.0741 49.82348 258.8904 725.6605 930.4877
0
200
400
600
800
1000
1200
DIGIT VIGILANCE - TIME
PRE POST
1 2 3 4 5
PRE 6.148148 0.5083455 2.641441 5.103229 7.193067
POST 7.259259 0.3524137 1.831195 6.534863 7.983656
0
1
2
3
4
5
6
7
8
9
VISUOSPATIAL N BACK TASK 1 - HIT
PRE POST
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1 2 3 4 5
PRE 2.851852 0.5083455 2.641441 1.806933 3.896771
POST 1.703704 0.3492557 1.814786 0.9857984 2.421609
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
VISUOSPATIAL N BACK TASK1 - OMISSION
PRE POST
1 2 3 4 5
PRE 4.814815 0.7435133 3.863409 3.286501 6.343128
POST 2.666667 0.5202454 2.703274 1.597287 3.736046
0
1
2
3
4
5
6
7
VISUOSPATIAL N BACK TASK1 -
COMMISSION
PRE POST
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1 2 3 4 5
PRE 3.518519 0.2941518 1.528458 2.913881 4.123156
POST 4.185185 0.1851852 0.9622504 3.804532 4.565839
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
VISUOSPATIAL  WORKING MEMORY 
SPAN1
PRE POST
1 2 3 4 5
PRE 0.8888889 0.2939724 1.527525 0.28462 1.493158
POST 2.111111 0.3710819 1.928198 1.348341 2.873881
0
0.5
1
1.5
2
2.5
3
3.5
VISUOSPATIAL WORKING MEMORY 
SPAN 2
PRE POST
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1 2 3 4 5
PRE 163.8519 27.12474 140.9443 108.0962 219.6075
POST 126.1111 13.95591 72.51702 97.42433 154.7979
0
50
100
150
200
250
TRAIL A - TIME
PRE POST
1 2 3 4 5
PRE 286.1852 33.43847 173.7514 217.4514 354.9189
POST 219.7407 19.53852 101.5251 179.5787 259.9027
0
50
100
150
200
250
300
350
400
TRAIL B - TIME
PRE POST
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COMPARISON OF EACH PARAMETERS  
BETWEEN TWO GROUPS 
Means of digit vigilance TIME of both ATOMOXETINE and 
METHYLPHENINDATE groups. 
 
ANOVA Table 
 F Sig. 
DVT TIME pre * 
Group 
Between Groups (Combined) 1.556 .218 
Within Groups   
Total   
DVT TIME POST 
Group 
Between Groups (Combined) .083 .774 
Within Groups   
Total   
The means of difference of pre and post of digit vigilance time of both 
ATOMOXETINE and METHYLPHENINDATE groups are not found to be 
statistically significant by ANOVA test. 
1 2 3 4 5
PRE 3.888889 0.8445119 4.388213 2.15297 5.624808
POST 2.148148 0.7055008 3.66589 0.6979705 3.598326
0
1
2
3
4
5
6
TRAIL B - ERROR
PRE POST
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Means of number of digit vigilance error of both ATOMOXETINE and 
METHYLPHENINDATE groups  
ANOVA Table 
 F Sig. 
DVT_diff * Group 
Between Groups (Combined) 1.205 .277 
Within Groups   
Total   
 
2. The means of difference of pre and post of digit vigilance error of both 
ATOMOXETINE and METHYLPHENINDATE groups are not found to 
be statistically significant by ANOVA test. 
Difference between Means of Verbal N Back hits pre and post  
ANOVA Table 
 F Sig. 
TRDVhitpr * 
Group 
Between Groups (Combined) .066 .798 
Within Groups   
Total   
TRDVhitpo * 
Group 
Between Groups (Combined) .000 1.000 
Within Groups   
Total   
DVhit_diff * 
Group 
Between Groups (Combined) .069 .793 
Within Groups   
Total   
The means of difference of pre and post of hit of verbal N back of both 
atomo and methy l groups are not found to be statistically significant by 
ANOVA test. 
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1. Means of verbal N Back omission  
ANOVA Table 
 F Sig. 
TRAver1ompr * 
Group 
Between Groups (Combined) .119 .731 
Within Groups   
Total   
TRAver1oppo * 
Group 
Between Groups (Combined) .024 .877 
Within Groups   
Total   
Aver1_diff * Group 
Between Groups (Combined) .065 .799 
Within Groups   
Total   
 
The means of difference of pre and post of verbal N Back omission of 
both atomo and methyl groups are not found to be statistically significant by 
ANOVA test. 
Means of difference between pre and post of verbal N Back commission  
ANOVA Table 
 F Sig. 
TRAver1compr * 
Group 
Between Groups (Combined) 1.973 .166 
Within Groups   
Total   
TRAver1compo * 
Group 
Between Groups (Combined) 1.751 .192 
Within Groups   
Total   
Aver1com_diff * 
Group 
Between Groups (Combined) .249 .620 
Within Groups   
Total   
 
The means of difference of pre and post of verbal N Back commission 
of both Atm and MPH groups are not found to be statistically significant by 
ANOVA test. 
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Difference in Means of Hits of verbal N Back 2  
ANOVA Table 
 F Sig. 
TRAver1hitpr * Group 
Between Groups (Combined) .076 .784 
Within Groups   
Total   
TRAver1hitpo * Group 
Between Groups (Combined) 1.607 .211 
Within Groups   
Total   
Aver1hit_diff * Group 
Between Groups (Combined) 2.330 .133 
Within Groups   
Total   
 
The means of difference of pre and post of verbal N Back hit of both Atm and 
MPH groups are not found to be statistically significant by ANOVA test. 
Difference of Means of verbal N Back 2 Omissions pre and post  
ANOVA Table 
 F Sig. 
TRAver2ompre * 
Group 
Between Groups (Combined) .071 .791 
Within Groups   
Total   
TRAver2ompo * 
Group 
Between Groups (Combined) 1.607 .211 
Within Groups   
Total   
Aver2om_diff * Group 
Between Groups (Combined) 2.172 .147 
Within Groups   
Total   
 
The means of difference of pre and post of verbal N Back 2 omissions of 
both Atm and MPH groups are not found to be statistically significant by 
ANOVA test. 
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Difference in Means of pre and post of trail A time of both atomo and 
methyl groups  
ANOVA Table 
 F Sig. 
TRAtriAtimpr * 
Group 
Between Groups (Combined) .568 .454 
Within Groups   
Total   
TRAtriAtipo * Group 
Between Groups (Combined) 1.006 .321 
Within Groups   
Total   
TrialAtime_diff * 
Group 
Between Groups (Combined) .078 .781 
Within Groups   
Total   
 
The means of difference of pre and post of Trail A time of both Atmand 
MPH groups are not found to be statistically significant by ANOVA test. 
Difference in Means visuospatial N BACK TASK 1 hits  
ANOVA Table 
 F Sig. 
TRAver2hitpr * 
Group 
Between Groups (Combined) .301 .586 
Within Groups   
Total   
TRAver2hitpo * 
Group 
Between Groups (Combined) .021 .885 
Within Groups   
Total   
Aver2hit_diff * 
Group 
Between Groups (Combined) .209 .649 
Within Groups   
Total   
 
The means of difference of pre and post of visuospatial card 1 hit of 
both atomo and methyl groups are not found to be statistically significant by 
ANOVA test. 
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Difference in means of visual-spatial N BACK TASK1 omission  
ANOVA Table 
 F Sig. 
TRAvisC1ompr * 
Group 
Between Groups (Combined) .043 .837 
Within Groups   
Total   
TRAvisC1ompo * 
Group 
Between Groups (Combined) .158 .693 
Within Groups   
Total   
Avisc1om_diff * 
Group 
Between Groups (Combined) .003 .958 
Within Groups   
Total   
 
The means of difference of pre and post of visuospatial card1 omission 
of both atomo and methyl groups are not found to be statistically significant by 
ANOVA test. 
10. Difference in Means of commissions of visuospatial N BACK TASK 1 
of both groups  
ANOVA Table 
 F Sig. 
TRAvisC1copr * 
Group 
Between Groups (Combined) 3.069 .086 
Within Groups   
Total   
TRAvisC1copo * 
Group 
Between Groups (Combined) 1.717 .196 
Within Groups   
Total   
Avisc1co_diff * Group 
Between Groups (Combined) 1.115 .296 
Within Groups   
Total   
 
The means of difference of pre and post of visuospatial card 1 
commission of both atomo and methyl groups are not found to be statistically 
significant by ANOVA test. 
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1. Difference between Means of visuo-spatial N BACK TASK2 hits  
ANOVA Table 
 F Sig. 
TRAviC1hitpr * 
Group 
Between Groups (Combined) .283 .597 
Within Groups   
Total   
TRAviC2hitpo * 
Group 
Between Groups (Combined) 2.804 .100 
Within Groups   
Total   
Avisc2hit_diff * 
Group 
Between Groups (Combined) .744 .392 
Within Groups   
Total   
 
The means of difference of pre and post of visuospatial card 2 hits of 
both atomo and methyl groups are not found to be statistically significant by 
ANOVA test. 
Difference between Means of visuospatial N BACK TASK2 omissions 
ANOVA Table 
 F Sig. 
TRAviC2ompr * 
Group 
Between Groups (Combined) .004 .949 
Within Groups   
Total   
TRAviC2ompo * 
Group 
Between Groups (Combined) 2.182 .146 
Within Groups   
Total   
Avic2omt_diff * 
Group 
Between Groups (Combined) 1.041 .312 
Within Groups   
Total   
 
The means of difference of pre and post of visuospatial card 2 omissions 
of both atomo and methyl groups are not found to be statistically significant by 
ANOVA test. 
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2. Difference in Means of pre-and post of visuospatial N BACK 
TASK2 commissions of both groups  
ANOVA Table 
 F Sig. 
TRAviC2copr * 
Group 
Between Groups (Combined) 5.038 .029 
Within Groups   
Total   
TRAviC2copo * 
Group 
Between Groups (Combined) 4.771 .033 
Within Groups   
Total   
Avic2cot_diff * 
Group 
Between Groups (Combined) .001 .971 
Within Groups   
Total   
 
The means of difference of pre and post of visuospatial card 2 
commissions was found to be statistically significant of both atomoxetine 
and methyl groups by ANOVA test. Methylphenidate group has less 
number of commissions. 
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3. Difference in Means on Comparison of visuospatial WORKING 
MEMORY SPAN 1 pre and post of both groups  
ANOVA Table 
 F Sig. 
TRAvispB1pr * 
Group 
Between Groups (Combined) .275 .602 
Within Groups   
Total   
TRAstr1timpo * 
Group 
Between Groups (Combined) .058 .811 
Within Groups   
Total   
VispB1_diff * Group 
Between Groups (Combined) .668 .418 
Within Groups   
Total   
 
The means of difference of pre and post of visuospatial block 1 of both  
Atm and methyl groups are not found to be statistically significant by ANOVA 
test. 
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Difference in Means of visuospatial WMS 2 pre-and post of both  Atm and 
methyl groups  
ANOVA Table 
 F Sig. 
TRAvispB2pr * Group 
Between Groups (Combined) .855 .359 
Within Groups   
Total   
TRAvispB2pos * 
Group 
Between Groups (Combined) .086 .771 
Within Groups   
Total   
VispB2_diff * Group 
Between Groups (Combined) .303 .584 
Within Groups   
Total   
 
The means of difference of pre and post of visuospatial block2 of both  
Atm and methyl groups are not found to be statistically significant by ANOVA 
test. 
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Difference in Means of trail A error in between pre and post of both  
Atm and methyl groups  
ANOVA Table 
 F Sig. 
TRAtrAerrpr * Group 
Between Groups (Combined) .038 .847 
Within Groups   
Total   
TRAtriAerrpo * Group 
Between Groups (Combined) .075 .785 
Within Groups   
Total   
TrialAerror_diff * 
Group 
Between Groups (Combined) .135 .715 
Within Groups   
Total   
 
The means of difference of pre and post of trail A error of both  Atm and 
MPH groups are not found to be statistically significant by ANOVA test. 
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Difference in means of trail B time of pre-and post of  Atm and MPH 
groups  
ANOVA Table 
 F Sig. 
TRAtriBtipr * Group 
Between Groups (Combined) .324 .572 
Within Groups   
Total   
TRAtrBtipos * Group 
Between Groups (Combined) .088 .768 
Within Groups   
Total   
TrialBtime_diff * 
Group 
Between Groups (Combined) .329 .569 
Within Groups   
Total   
 
The means of difference of pre and post of trail B time of both  Atm and 
MPH groups are not found to be statistically significant by ANOVA test. 
Difference in Means of trail B error of pre-and post of both Atm and MPH 
groups  
ANOVA Table 
 F Sig. 
TRAtrBerpr * Group 
Between Groups (Combined) 2.804 .100 
Within Groups   
Total   
TRAtrBerpo * Group 
Between Groups (Combined) 3.312 .075 
Within Groups   
Total   
TrialBerror_diff * 
Group 
Between Groups (Combined) .131 .719 
Within Groups   
Total   
 
The means of difference of pre and post of trail B error of both atoms 
and MPH groups are not found to be statistically significant by ANOVA test. 
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The difference in significance was also tested using Nonparametric tests 
Mann-Whitney U Test. No two tailed significance was obtained.  
 
Methylphenidate (Pre to Post) 
Sl.No. Test p value Prob>Z 
1 Digit Vigilance - Error 0.0187   
2 Verbal Nback1 - Hit 0.0278   
3 Verbal Nback1 - Omission 0.0257   
4 Verbal Nback2 - Hit 0.0017   
5 Verbal Nback2 - Omission 0.0015   
6 Verbal Nback2 - Commission 0.005   
7 Visuospatial Nback Task1 - Omission 0.0422   
8 Visuospatial Nback Task1 - Commission 0.0369   
9 Visuospatial Nback Task2 - Hit 0.0454   
11 Trail A - Time 0.0000   
13 Trail B - Time 0.0013   
1 Visuospatial Working Memory Span   0.006 
2 Trail A - Error   0.0541 
3 Trail B - Error   0.0019 
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Atomoxetine (Pre to Post) 
Sl.No. Test p value Prob>Z 
1 Digit Vigilance - Time 0.0249   
2 Visuospatial Nback Task1 - Hit 0.0161   
3 Visuospatial Nback Task1 - Omission 0.0122   
4 Visuospatial Nback Task1 - Commission 0.0006   
5 Visuospatial Working Memory Span1 0.0214   
6 Visuospatial Working Memory Span2 0.0024   
7 Trail B - Time 0.0099   
8 Trail B - Error 0.0218 0.0463 
 
Name of the 
outcome and test 
Name of 
statistical test 
of significance 
Test 
statistics 
Significance 
level 
Comments 
Combined omission and commission 
error together  
   
Verbal N Back 2 
error ATM 
ttest 4.42 0.0002 ATM is superior 
to MPH 
Verbal N Back 2 
error MPH from 
pre to post  
ttest 2.25 0.032  
Visuospatial card1 
for atomoxetine  
ttest 3.14 0.0041 SIGNIFICANT 
Visuospatial card1 
for 
methylphenidate 
ttest 4.14 0.0004 Methylphenidate 
is superior 
Shifting time 
Pre to post of 
Atomoxetine 
Ttest of 
difference 
between means  
3.217 0.0034  
Pre to post of 
Methylphenidate 
ttest -5.80 0.000 Both are 
significant 
however MPH is 
more superior 
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DISCUSSION 
                 
Till date, there have been no Indian studies so far to compare the 
efficacy of two group of drugs in improving cognitive performance in children 
suffering from ADHD. Here a first head to head comparison of the two class of 
drugs have been done using a Randomized control trial with adequate blinding. 
Overall, we have found both drugs to be efficacious in improving all the 5 
executive function parameters from baseline viz, 1. Visuospatial working 
memory 2.visuospatial working memory span3. Verbal working memory. 4. 
Sustained attention 5. Set shifting . All tests performed using standardized 
neuropsychological battery of tests developed at the National Institute of 
Mental Health and Neurosciences, Bangalore. The primary aim of the study 
was to compare the improvements in executive function parameters between 
Methylphenindate and Atomoxetine after 4 weeks of continuous treatment 
              The Study was conducted for the age group varying from 7 to 12 
years, for both Atomoxetine and Methylphenidate drugs. There was 29.6% of 
7&8 year old children, 27.8% of 9&10 year old children and 42.6% of 11&12 
year old children.  
Among the total set of children, 81.5% were Male and 18.5% were 
females. The set consists of 85.2% of Hindus, 5.6% of Christians, 7.4% of 
Muslims and one orphan child. 
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All the children in our study brought to the out patient department had 
complaints of poor academic performance. Out of 54 children, 88.8% studied 
in English Medium and 11.1% in Tamil medium schools.68.5% of them had 
suffered failures in one or more subjects in school. None of them secured A 
grade in class. Out of the total 42.5% reported to be having poor social 
relations and frequent peer conflicts. Out of the 54, 53.7% were first born and 
48.1% reported a positive family history in either of the two parents and 20% 
had positive history of psychiatric illness in first degree relative.Only 29.6% 
had a parent with substance dependence. 
             In our study sample, 68.5% had a comorbidity of specific learning 
disorder. Tic disorder was seen in 4 and anxiety disorder was there in 6 cases.  
Developmental delay was reported in only one case and 10 children had a past 
history of seizures. 
Among the stimulant drugs, Methylphenidate is the most widely used 
and thoroughly studied drug. It is one if the oldest drug to be used in this 
condition. (Green Hill etal 2002, Faraone etal 2004)216, 217. There are two 
widely used preparations of the drug namely immediate release MPH and 
osmotic release oral system (OROS MPH). That have been shown to be 
efficacious in ADHD children and adults. (Gau etal 2006, Kessler etal 
2005)218,219. In our study we have used IR preparation of Methylphenidate with 
slow titration of doses starting from 5mg per day upto maximum dose of 60 
mg. Atomoxetine was started at a dose of 0.5 mg/kg and slowly titrated 
upwards. 
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WORKING MEMORY 
It was one of the major executive function parameter assessed in our 
study. It was analyzed in two different halves i.e. visuospatial working memory 
and verbal working memory. For visuospatial working memory assessment two 
tests were used namely Visuospatial N Back Task and Working Memory Span 
Task (which assess the working memory span), whereas Verbal N Back Task 
part one and two was used for assessing verbal working memory. All the three 
tests were administered at baseline and four weeks after starting the drug. 
METHYLPHENINDATE AND WORKING MEMORY 
For the assessment of verbal working memory Verbal N Back Task was 
used. In the first part of the test Methylphenidate could improve the number of 
hits or correct responses. The significance of mean of difference was found to 
be -2.33 and the p value of 0.0278 indicated a significant improvement in the 
number of correct responses.  
The number of omissions in part one also got reduced from baseline. 
(Mean/SD-1.22 to 0.66) Thus there was statistically significant reduction in 
omission errors in part one test of verbal working memory after administration 
of MPH. Whereas commission errors even though showed improvements from 
baseline (mean/SD 1.03 to 0.814) it could not be accounted for statistically in 
paired t test measurements. (p value0.4)  
In part 2 of verbal N back task, MPH showed a statistically significant 
increase in correct responses from baseline (mean/sd-5.18 to 6.29) (p 
value0.0017). The omission errors improved drastically from pre-drug 
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measurements and it was also found to be highly significant. (p value-0.0015). 
The errors by commission also got significantly reduced after MPH drug 
treatment. (Mean/SD-2.85 to 1.55) (p-0.005) 
            When the total number of errors (omissions plus commissions) were 
combined together and analyzed, in Verbal N Back Task1 the drug failed to 
show significant improvements from baseline. Whereas in Verbal N Back task 
2 it showed significant improvements from pre drug values(p-0.03 for MPH) 
Thus, to conclude while assessing verbal working memory we found out 
that MPH significantly improved the correct responses of verbal n back task 
part 1 and 2 from the baseline showing improvements in verbal working 
memory. The commission errors which also measures the level of impulsivity 
improved in part 2 but not in part one. The omission errors which also indicate 
the level of inattention along with working memory impairments were 
improved significantly by MPH in both parts of the test. While assessing total 
number of errors the drug showed a significant improvement in part two from 
the baseline. 
During the assessment of visuospatial working memory MPH did not 
show much favorable results when compared to baseline part 1 of N Back card 
task, the differences in hits were found to be just one tail significant. (p<t 0.05). 
Omission errors and commission errors improved significantly in part 1 test 
from baseline. Whereas in part 2 test the number if correct responses or hits 
showed improvements from baseline (mean diff t=-2.10) which was found to 
be statistically significant too (p>t=0.0454) Whereas we found that both 
omission and commission errors were not significantly improved from 
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baseline. We tried to attain significance with both paired t tests and non-
parametric Wilcoxon sign rank test and that too showed unfortunately 
insignificant results. Whereas when the errors were combined and analyzed, 
Methylphenidate showed improvements in reduction of total number of errors 
from baseline. 
              In visuospatial working memory span task, part 1 did not show any 
statistically significant improvements from pretreatment values when assessed 
using Wilcoxon signed rank test. (Prob >z =0.13) Here the baseline values were 
itself elevated in most of the cases. Thus, it could be the reason for the lack of 
significant improvement with treatment. Whereas in the case of visuospatial 
working memory span task2 that scored very low baseline values (as the test 
was difficult and required high levels if working memory) the difference in 
post and pre drug measurements were found to be highly significant 
statistically. 
To conclude, visuospatial working memory was assessed by two 
groups of tests, namely Visuospatial N Back task (for measuring 
visuospatial working memory) and Visuospatial working memory span 
task (for measuring visuospatial working memory span); each consisting 
of 2 parts. Methylphenidate, when administered in these children for a 
period of four weeks improved the visuospatial working memory 
parameters by causing increase in the number of correct responses and the 
total number of errors significantly in first part if the test.  
In Visuospatial working memory span task which measured the 
working memory span improvements of MPH from baseline, highly 
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statistically significant improvements in values were obtained from the low 
baseline values whereas higher baseline values did not show much 
improvements. 
Rhodes et.al in 2006 demonstrated that Methylphenidate had no effect 
on spatial working memory in male children with ADHD220 and Biederman 
replicated the same finding in adults221. Whereas many other researchers 
(Kempton et.al 1999, Barnett Et.al 2001, Bedard etal 2004, Mehta etal 2004,) 
questioned the inefficacy222 to 225.  
ATOMOXETINE AND WORKING MEMORY 
During the assessment of verbal working memory through Verbal N 
Back task, in part one of the test, Atomoxetine improved the mean of correct 
responses from 7.66 to 8.29 but it was not found to be statistically significant. 
(P > |t| = 0.0909). The errors made by commission also got reduced from a 
mean of 2.18 to 1.59 but could not be accounted statistically. (P > |t| = 0.3841) 
The number of omissions got reduced from a mean of 1.3 to 0.70 and was 
found to be one tail significant. (P > t = 0.0400). In part two test, the number of 
correct responses showed significant improvement from baseline, whereas 
omission / commission errors failed to show the same. (P > t = 0.0511)  
(P > |t| = 0.2171 ). When the total number of errors (omission + commission) 
were compared from baseline, Atomoxetine showed a highly significant 
improvement in verbal Nback part2 task (p = 0.0002), whereas failed to do so 
in Part 1. 
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Among the visuospatial working memory Nback task scores 
Atomoxetine showed significant improvement in the number of hits, omissions 
and commissions from baseline (p = 0.01, 0.012 & 0.0006 resp.) and fail to do 
so in second part of the test. Whereas when the errors made were combined 
together, Atomoxetine treatment showed significant improvements in reduction 
of errors from the baseline. (p=0.0041) 
              Thus, Atomoxetine showed significant improvements in visuospatial 
working memory and not much improvement in verbal working memory 
parameters from baseline in N Back tests. 
              In verbal N Back 2, correct responses significantly improved from 
baseline; but not in N Back part 1. There were only minimal improvements in 
scores of inattention and impulsivity. When the errors were combined and 
analyzed, (inattention +impulsivity) Atomoxetine showed highly significant 
improvements from baseline scores. 
              Whereas in visuospatial working memory span task 
administration of Atomoxetine showed significant improvements from the 
baseline in working memory parameters. Hence like Methylphenidate, 
Atomoxetine could improve the working memory span from the baseline. 
METHYLPHENINDATE AND ATOMOXETINE COMPARISON OF 
WORKING MEMORY 
While assessing verbal working memory, the mean hits in the two 
groups of drugs at baseline were 7.67 and 8.30 after 4 weeks of drug intake. 
The means of difference of baseline and post treatment values of both group of 
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drugs did not yield any statistically significant differences in our study. The 
mean values of omissions were found to be 1.37 at baseline and 0.70 after 
treatment. Both omission and commission errors did not show much 
significance when analyzed between two groups. Similar results were obtained 
in the part two test of verbal N Back. Neither omissions nor commissions 
showed statistical significance between two groups, when analyzed separately 
whereas the total number of errors was significantly improved by Atomoxetine 
when compared to Methylphenidate. (p-0.0002 Atm Vs p0.03 of MPH). 
While analyzing visuospatial working memory between two groups, the 
mean hits in the two groups of drugs at baseline were 6.15 and 7.26 after 4 
weeks of drug intake. The means of difference of baseline and post treatment 
values of both group of drugs did not yield any statistically significant 
differences in our study. Neither hits nor omissions showed statistical 
significance between two groups, when analyzed separately whereas the total 
number of errors was significantly improved by Methylphenidate when 
compared to Atomoxetine.(p-0.0004 MPH Vs p-0.004 of Atm). 
In second part of visuospatial working memory task, even though 
commission errors did not show statistical improvements within groups when 
analyzed by ‘t’ test, intergroup comparison by ANOVA yielded statistically 
significant means of differences in the two groups. There was lesser number of 
commission errors in MPH. (sig-0.03) 
A comparative study conducted by li Yang etal in 2012215 compared 85 
subjects taking Methylphenidate and 57 children taking Atomoxetine. In the 
study, visual working memory was assessed by Rey Complex Figure test and 
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verbal working memory using Digit span and reverse digit span. They found 
out that both the drugs lead to significant improvements in working memory 
parameters when compared to baseline whereas there were no significant 
differences noted between the two groups. In our study even though we 
obtained a similar finding in working memory scores, Atomoxetine was found 
to be superior over Methylphenidate in the reduction of verbal working 
memory errors whereas MPH gained superiority in visuospatial working 
memory errors (commission alone and combined). The contradiction in the 
above finding could be explained by the smaller sample size and thus needs 
further clarification with a higher sample. 
To conclude, we found Atomoxetine to be superior than 
methylphenidate in improving the verbal working memory, and 
Methylphenidate to be superior to Atomoxetine in Visuospatial working 
memory. 
SUSTAINED ATTENTION 
In our study sustained attention or the ability to sustain one’s own 
attention for a prolonged period of time was measured using the Digit Vigilant 
test which measures both the time taken to perform the test and errors made 
(omissions plus commissions) 
ATOMOXETINE AND SUSTAINED ATTENTION 
The mean time taken to perform the Digit Vigilant test was found to be 
958.07 at the baseline and got reduced to 828.07 after 4 weeks of treatment 
with Atomoxetine. The mean difference was found to be 130 and was 
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statistically significant. (P > t = 0.0125) Whereas the errors made (sum of 
omissions and commissions) even though showed reductions from drug naïve 
state (mean 51 to 43.1), the marginal difference was not found to be 
statistically significant. 
Thus, Atm even though improved the processing speed as assessed 
by Digit Vigilance test could lead to only minimal improvements in 
sustained attention scores that could not be proven statistically. 
Susan Shur Fen Gau etal found that Atomoxetine improved sustained 
attention in 30 boys with ADHD226. Their sample size was almost similar to 
that of our study but more frequent assessments were made at 4 weeks and 12 
weeks. Significant improvements in sustained attention was observed after 12 
weeks of assessment. In our study we might have failed to detect significant 
improvements due to early assessment at 4 weeks and lack of further follow up. 
Spencer and colleagues in 1998 failed to prove that Atomoxetine improved 
sustained attention measures by CPT227 whereas Susan Shur etal Barton etal 
2005228 and the NE hypothesis by De Martino etal 2008 and Coul etal 2004 
refutes the above finding229. Our finding of reduced processing speed has been 
supported by the above studies (Barton etal 2005, Chamberlain etal 2006,Susan 
ShurFen Gau etal) 226, 228, 230 
METHYLPHENINDATE AND SUSTAINED ATTENTION 
          When exposed to Methylphenidate, all ADHD subjects showed a 
minimal reduction from the baseline values and it was not statistically 
significant. (Pre mean 864.29 post mean 808.51) (p value-0.17) (mean 
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difference - 55.77) Unlike Atomoxetine, statistically significant improvements 
in the total number of errors were shown by Methylphenidate. (P > t = 0.0094) 
Thus, treatment with Methylphenidate was shown to improve 
sustained attention but not the speed of processing. 
Our present finding of improved sustained attention is in keeping with 
the studies of M V Solanto etal and D H Douglas etal231,232. The lack of 
improvement in cognitive processing needs further research. 
SUSTAINED ATTENTION-COMPARISON BETWEEN TWO GROUPS 
The time taken to perform Digit vigilance test was compared within the 
two groups. The mean / SD was found to be 958.07/301.86 at baseline and 
828.07/258.8 after four weeks of drugs. Overall, the minimum and maximum 
time taken to perform the tests in the two groups were found to be 428s and 
1515 sec at baseline and 401 and 1410 seconds respectively. F ratio was found 
to be 1.556 at baseline and 0.083 after treatment with p values> 0.05 in 
comparison of the two groups. Thus, even though the means of difference of 
the time taken to complete the test were found to be higher for 
Methylphenidate group it was not found to be statistically significant. 
Total number of errors made were compared. Mean/SD was 130.0/283.7 
for the atomoxetine group and 55 /207 for the methylphenidate group and a 
total of 92/248.9 with an F ratio of 1.205 and a P value of 0. 277.Mean 
difference was found to be higher for the Atomoxetine group (24.18) than the 
MPH group (16.03) but no statistical significance could be attributed for the 
difference. 
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An American study conducted by Anne Claude etal has compared 
sustained attention improvements between Atomoxetine and OROS MPH233. In 
contrast to our study they could prove statistically that OROS MPH was more 
superior to Atm in reducing the omission errors and commission errors did not 
improve with either of the two drugs. Post hoc paired t tests showed a 
significant reduction in omission errors following OROS MPH (p-0.001) but 
not Atomoxetine treatment. (p-0.69). Unlike our study with a sample size of 27 
in each group, 30 in controls comprising a total of 84(54 in cases and 30 in 
controls) they compared 77 cases of Atomoxetine and 52.4 cases of 
Methylphenidate. When we used manually administered NIMHANS battery 
they had used a computer administered test known as Conner’s Continuous 
Performance Test II Version 5 to assess sustained attention. While we assessed 
the total number of errors as per the NIMHANS Manual they analyzed 
omission and commission errors separately and did not assess the total number 
of errors. Our finding is inconsistent with theirs such that we found 
Atomoxetine to be superior in reducing total errors though not statistically 
significant Thus, low sample Size and the use of manual test battery could be 
the reason for the discrepancy in results and our failure in attaining statistical 
significance for our finding. 
SET SHIFTING 
Set shifting, which is a measure of cognitive flexibility was measured 
using Trail making test A and B. The time taken to perform Trail A and B 
denoted the processing speed and the errors denoted the ability to shift one’s 
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attention from one set task to another ka set shifting. Another parameter known 
as shifting time was assessed (difference in time taken by Trail A & B). 
ATOMOXETINE AND SET SHIFTING 
After 4 weeks of treatment with Atm, the time taken to perform Trail A 
test was found to be shortened and the reduction was just one tail significant. 
(p<t=0.0426) (mean/SD=37.7/109.6). Whereas the errors made were not found 
to be significantly elevated when measured using Wilcoxon signed rank test 
(Prob>z=0.23) 
Whereas in Trail B, Children on Atomoxetine were able to improve their 
processing speed and the difference in pre-and post-values were highly 
statistically significant (p>t=0.009)  
The errors made in Trail B test which clearly denotes the set shifting 
ability were found to have been improved from baseline values and were 
detected to be significant by both non paired t test and Wilcoxon sign rank test. 
          Therefore, set shifting ability and processing speed were improved 
by 4 weeks of treatment with Atomoxetine in our sample of ADHD 
children. 
          Even though older studies like Spencer etal227 in 1998 and Chamberlien 
etal in 2007 failed to demonstrate improvements in cognitive flexibility by 
Atomoxetine, The above finding is consistent with the study by Susan Shur Fen 
Gau etal in 30 drug naïve children226.Our findings also supported the findings 
of animal studies conducted in rats by Newcorn etal in 2008214. 
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METHYLPHENINDATE AND SET SHIFTING 
           Treatment with Methylphenidate also showed significant improvements 
in Trail making scores. The time taken to complete the Trail making test A 
improved from baseline and the difference was highly significant when 
analyzed statistically. (p>t=0.00). Even in Trail B test, the time taken to 
perform the test got reduced which also showed high degrees of statistical 
significance. (p>t=0.0013) The number of errors also got reduced significantly 
from drug naïve state in both Trail tests.  
Trail B errors which are highly indicative of set shifting capability 
showed a highly statistical significance of difference in Wilcoxon signed rank 
test. (prob. z=0.001). 
Hence Methylphenidate drug was found to be highly effective in 
improving the speed of processing and set shifting capacity from baseline 
values after 4 weeks if continuous treatment. 
SET SHIFTING-COMPARISON BETWEEN TWO GROUPS 
The time taken to perform Trail A test, when compared between 
Atomoxetine and Methylphenidate groups, the mean/SD values for pre-and 
post-assessments were found to be 163.85/140.9 and 126.11/72.5 respectively.  
And the F values being 0.568 in baseline group and 1.006 after 4 weeks. 
The mean difference for the time taken was higher for the MPH group (34.25) 
when compared to the Atm group (30.7) but the results were not found to have 
any statistical significance in our study. Errors made while performing the test 
showed a mean of 1.19 in baseline and 0.48 after 4 weeks and a SD of 2.321 
and 0.753 respectively. F ratio of comparison was 0.038 (pre) and 0.075(post 
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treatment). The mean difference was higher in the MPH group (0.6) then Atm 
group (0.5) but could not be accounted for statistically. 
In Trail B test, mean difference of errors in the MPH group was 1.5 and 
Atomoxetine group was 1.4 whereas the time taken showed a mean difference 
if 57.5 in the former and 48.6 in the latter.  
Thus, improvements in both time taken to perform the test and the 
errors made (omissions and commissions) were higher for 
Methylphenidate when compared to Atomoxetine in both Trail A and 
Trail B tests but unfortunately, no statistical significance was obtained in 
any of these parameters. Whereas while assessing shifting time between 
two groups, Methylphenidate is found to be superior than Atomoxetine (p 
–0.000Vs p-0.003). 
             Li Yang etal used the similar Trail making test A and B to assess 
shifting time. It was found to be still longer than control group in children 
taking MPH215. At the end even though scores were higher for the OROS MPH 
group, similar to our study it was not found to be statistically significant. 
RESPONSE INHIBITION 
In our study, response inhibition was measured using Stroop test but as a 
good proportion of our study sample had learning disabilities, the test could be 
performed only in very limited number of sample with gross discrepancies 
between arms and thus statistical analysis could not be done. 
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CONCLUSION 
1. Eventhough both the drugs were efficacious in improving several 
executive functions parameters from the baseline, most of tests did not 
reveal much statistically significant differences between two groups.  
2. We found Atomoxetine to be superior than methylphenidate in 
improving the verbal working memory errors, and Methylphenidate to 
be superior to Atomoxetine in Visuospatial working memory errors. 
3. Methylphenindate was found to be superior to Atomoxetine in 
improving the shifting time; a measure of cognitive flexibility. 
4. Methylphenindate was also found to be superior than Atomoxetine in 
working memory errors related to impulsivity. 
5. The present study results in Comparison with previous studies show that 
Atomoxetine may take more time than Methylphenidate in improving 
sustained attention scores. 
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STRENGTHS OF THE STUDY 
1. It is the first of its kind to be conducted in India. All through the world, 
even though there are various RCT s comparing the two drugs with 
placebo head to head comparison studies in children are very sparse. 
2. The study was conducted in the biggest tertiary care center in South 
India to where cases are referred from all parts of Tamil Nadu, some 
parts of Andhra Pradesh, Karnataka and Kerala harboring a good team 
of trained psychiatrists and clinical psychologists. 
3. Unlike many comparison studies where executive functions were 
assessed by scales alone, we have applied a wide range of 
neuropsychological tests taken from a standardized battery of tests to 
measure the parameters. 
4. Treatment was allocated by randomization and adequate blinding was 
done. 
5. Adequate screening of cases for intelligence was conducted with the 
help of trained clinical psychologists. 
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LIMITATIONS OF THE STUDY 
1. Despite continuous efforts made, finally we could arrive at a very 
small sample size due to the large number of attritions. 
2. Simple randomization methods were used for the allocation of cases 
into two arms of the study. 
3. A short period of four weeks follows up was done due to the time 
constraints. 
4. Due to the small sample size we were unable to exclude the children 
with co morbidity of seizure disorder and thus the cognitive 
impairment of antiepileptic drugs could not be nullified in the present 
study. 
 
 
 
 
 
 
 
 
 91 
FUTURE DIRECTIONS-RESEARCH AND CLINICAL 
IMPLICATIONS 
As the two group of drugs has been found to be effective and there are 
various conflicting results obtained in our study, extension of the research with 
a large sample size and more frequent follow ups are required to generalize our 
study findings. This would help in tailoring of the drug treatment as per the 
child s baseline executive function parameters. 
All children diagnosed with ADHD must be subjected to the 
neuropsychological battery of tests to detect the baseline executive function 
deficits. After selection of the appropriate drug, the child must be frequently 
followed up for the improvement in these parameters. 
The large number of drop outs from our study indicated that parents of 
ADHD children must be properly psycho educated  regarding the cognitive 
deficits and  the benefits of treatment in ADHD. 
Extensive awareness regarding the condition and its treatment should be 
implemented at the community level and to specific population like school 
teachers. 
Large scale follow up studies that also includes behavior responses and 
long term side effects of the drugs must be carried out in our population. 
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APPENDIX 
NIMHANS NEUROPSYCHOLOGICAL BATTERY 
 Two tests are taken as a measure of visuospatial working memory: 
visuospatial working memory span task and the N back Task (visual). 
Visuospatial working memory span task (Milner, 1971) 
Rationale:  
 This test is a measure of visuospatial working memory span.  
Material: 
 Five wooden cubes. 
Procedure: 
 The task consists of four cubes arranged in a row. The examiner taps the 
four cubes with at fifth cube. The tapping is performed in different sequences 
and the subject is required to repeat the sequence of four taps tapped by the 
examiner. Five trails of forward and five trials of reverse sequence are given. 
Number of taps remains the same for all the forward and reverse sequences. 
But each sequences different from the other. The number of correct sequences 
tapped by the subject for both the forward and reverse conditions together 
comprises the total score for the test.  
The test re-test reliability coefficient of the test is 0.57. 
 134 
Nback Task of Visuospastial working memory 
Nback task of visuospatial working memory measures storage, manipulation 
and rehearsal of spatial information. It consists of a 1back task and a 2back 
task. 1back task consists of a set of 36 cards. Each card has one dot on it. Dots 
are placed on spatially different location on each of these cards in an imaginary 
circle. The cards are successively placed on the table in the same location. Each 
card is presented at the rate of 2s per card. As each card is presented, the 
subject has to decide whether the location of the dot in the present card matches 
with the location of the dot in the card which appeared just before the present 
card. If so, the subject has to say ‘yes’ otherwise ‘no’. The 2back task also 
consists of a set of 36 cards. As each card is presented, the subject has to decide 
whether or not the location of the dot in the present card matches with the 
location of the dot which appeared two cards before the present card. If so, the 
subject has to say ‘yes’ otherwise ‘no’.  
Scoring: 
 1back Task & 2back Tasks are scored separately. Scoring is done in 
terms of number of correct responses called hits and the number of omissions / 
commissions called misses. 
The test re-test reliability coefficient of the two tests are 0.59 & 0.72 
respectively. 
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Verbal Working Memory: N back Task (Smith & Jonides, 1995) 
Rationale: 
 Nback Task (verbal) is a measure of verbal working memory. Material: 
List of phonemes and record form. 
Description: 
 Verbal working memory has three important components i.e. storage, 
manipulation of information and rehearsal. N back Task is based on the 
theoretical premise that two variables can affect verbal working memory i.e. 
word length and phonetic similarity. It consists of a ‘1 back task’ and a ‘2 back 
task’. The ‘1 back task’ consists of a list of phonemes. The list of phonemes is 
kept out of the subjects view. Each phoneme is presented at the rate of one 
phoneme per second. The subject is required to respond in terms of Yes or No 
for phonetically similar and dissimilar sounds respectively. The subject has to 
say ‘yes’ for each consecutively repeated sound and for the other sounds the 
response is ‘no’. In the ‘2 back task’ as each sound is presented the subject has 
to decide whether or not it matched the sound that appeared two items back in 
the sequence and if so the subject has to respond in terms of yes or no. In this 
condition the subject must always maintain representations of the two most 
recent sounds in memory to compare with the current one.  
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Scoring: 
 The Nback Task (verbal) obtains two scores. One score is called a hit 
that is the number of correct responses. The other score is called misses that is 
scored when the subject has missed a correct target and said ‘no’ for a phoneme 
when he should have said ‘yes’. Each of the two scores are obtained separately 
for the ‘1back’ and ‘2back’ tasks. 
The test re-test reliability coefficient of the two tests are 0.29 & 0.71 
respectively. 
Response Inhibition – Stroop Test 
 The Stroop test or Stroop color word test consists of a stimulus sheet, 
containing printed color names blue, green, red and yellow. The color of the 
print occasionally corresponds with the color designated by the word. The 
words are printed in 16rows and 11columns. The stimulus sheet is placed in 
front of the subject. The subject is asked to read the stimuli as fast as possible. 
The time taken to read all the 11 columns is noted down. Next the subject is 
asked to name the color in which the word is printed. This time also, the 
subject proceeds column wise and the time taken to name all the colors is noted 
down.  
Scoring: 
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 The reading time and the naming time were converted into seconds. The 
reading time was subtracted from the naming time to get the Stroop effect 
score. Uncorrected errors were noted down separately for both the phases. 
Digit Vigilance Test 
 The digit vigilance test consists of numbers 1 to 9 randomly ordered and 
placed in rows on a page. There are 30 digits per row and 50 rows on the sheet. 
The digits are closely packed on the sheet. The subject is asked to scan the 
sheet and cancel the target digits 6 & 9 as fast as possible, without cancelling 
other numbers. 
Scoring: 
1. Time taken to complete the test 
2. Error score :- Sum total of number of omissions and commissions 
Focused attention : Color Trails Test (D’ Elia, Satz, Uchiyama & White, 
1996) 
Rationale : 
Color Trails Test is a measure of focused attention. It is also a measure of 
mental or conceptual tracking and cognitive flexibility. Trail Making Test has 
been found to be highly sensitive to brain damage (O’Donnel, 1983). Larger 
than normal differences between Part ‘A’ and ‘B’ of this test have been 
interpreted as an indication of left lateralized lesions (Wheeler & Reitan 1963). 
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Material : 
 Color trail sample sheets, color trails A & B, stopwatch. 
Description : 
 Color trail tests (D’Elia et al., 1996) has been included in the present 
battery because of its wider capability. This test is designed to minimize the 
influence of language and covers a wide age range from childhood to 
adulthood. I has two parts, ‘Part A’ and ‘Part B’. On ‘Trail A’ circles numbered 
1 to 25 are in two colors yellow and pink. All odd numbered circles are pink 
and even numbered circles in yellow. The subject is required to serially connect 
the numbers 1 to 25, irrespective of the colors. ‘Trail B’ shows all numbers 
from 1 to 25 twice in pink and in yellow. The subject is required to connect the 
numbers serially from 1 to 25 alternating between pink and yellow circles and 
disregarding the numbers in circles of the alternate color. Time taken for both 
trail A and B are noted separately. Errors are also recorded. This test is loaded 
on rapid visual search and visuo-spatial sequencing factor as well as cognitive 
set shifting. Normative data for Color Trails was based on the performance of 
adults aged 18 years to 89 years. In children aged 5 years 11 months to 16 
years a steady age progression was noted. Girls completed ‘Color Trails B’ 
more quickly than boys (Spreen & Strauss, 1998). (The Color Trails Test can 
be obtained from the publishers of this test). 
Scoring: 
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Time taken in seconds and errors of omissions and commissions for ‘Trail A’ 
and ‘Trail B’ separately comprise the score for this test. 
The test re-test reliability coefficient of the two tests are 0.65 & 0.79 
respectively. 
 
 
 
 
              



































